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Signal transduction and activator of transcription 3 (Stat3) is activated by 
cytokines and growth factors in many cancers. Persistent activation of Stat3 
plays important role in cell growth, survival, and transformation through 
regulating its targeted genes.  
Previously, we found that mice with a deletion of the G protein-coupled 
receptor, family C, group 5, member a (Gprc5a) gene develop lung tumors 
indicating that Gprc5a is a tumor suppressor. In the present study, we examined 
he mechanism of Gprc5a-mediated tumor suppression. We found that epithelial 
cells from Gprc5a knockout mouse lung (Gprc5a-/- cells) survive better in vitro in 
medium deprived of exogenous growth factors and form more colonies in semi-
solid medium than their counterparts from wildtype mice (Gprc5a+/+ cells). The 
phosphorylation of tyrosine 705 on Stat3 and the expression of Stat3-regulated 
anti-apoptotic genes Bcl-XL, Cryab, Hapa1a, and Mcl1 were higher in the 
Gprc5a-/- than in Gprc5a+/+ cells. In addition, their responses to Lif were different; 
Stat3 activation was persistent by Lif treatment in the Gprc5a-/- cells, but was 
transient in the Gprc5a+/+ cells. The persistent activation of Stat3 by Lif in 
 v
Gprc5a-/- cells is due to a decreased level of Socs3 protein, a negative inhibitor 
of the Lif-Stat3 signaling. Restoration of Socs3 inhibited the persistent Stat3 
activation in Gprc5a-/- cells. Lung adenocarcinoma cells isolated from Gprc5a-/- 
mice also exhibited autocrine Lif-mediated Stat3 activation. Treatment of 
Gprc5a-/- cells isolated from normal and tumor tissue with AG490, a Stat3 
signaling inhibitor, or with dominant negative Stat3(Y705F) increased 
starvation-induced apoptosis and inhibited anchorage-independent growth.  
 
These results suggest that persistent Stat3 activation increased the 
survival and transformation of Gprc5a-/- lung cells. Thus, the tumor suppressive 
effects of Gprc5a are mediated, at least in part, by inhibition of Stat3 signaling 
through regulating the stability of the Socs3 protein. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Lung Cancer and Genetic Aberrations 
Lung cancer continues to be the leading cause of cancer death in both 
men and women in the United States and worldwide (Jemal et al., 2009). It is 
expected to account for 26% of all female cancer deaths and 30% of all male 
cancer deaths in United States in 2009 (Jemal et al., 2009). The fact that most 
lung cancer patients are diagnosed at advanced stages with metastasis when 
treatments are palliative causes the high mortality rate of this dreadful disease 
and high morality happens even in early stage. The main types of lung cancer 
are non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma 
(SCLC). Lung cancer development is the consequence of multiple stepwise 
molecular and histopathological changes in the airway epithelial cells leading to 
invasive carcinoma and adenocarcinoma (Wistuba and Gazdar, 2006). The 
development of lung cancer is often attributed to many risk factors including 
cigarette smoking (Doll and Peto, 1976; Doll et al., 1994; Hecht, 1999), radon 
gas (Catelinois et al., 2006), asbestos (O'Reilly et al., 2007), air pollution (Chiu 
et al., 2006; Coyle et al., 2006; Kabir et al., 2007) and lung diseases such as 
chronic obstructive pulmonary disease (COPD) (Turner et al., 2007; Young and 
Hopkins, 2010). Tobacco smoke contains over 60 known carcinogens (Hecht, 
2003) that have been implicated in lung carcinogenesis. Therefore, cigarette 
smoking is the major risk factor for lung cancer (Biesalski et al., 1998).  
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Figure 1. Ten Leading Cancer Types for Estimated New Cancer Cases and 
Deaths, by Sex, United States, 2009. Adapted from (Jemal et al., 2009). 
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Cigarette smoking has been estimated to account for 87% of lung cancer cases 
(90% in men and 85% in women) in the United States (Samet et al., 1988).  
However, about 10% of lung cancer patients are never smokers in the 
United States (Subramanian and Govindan, 2007; Subramanian and Govindan, 
2010). These reports suggest that other factors, including different genetic 
background of individuals, and gene-environment interactions may play 
important roles in the development of lung cancer (Alberg and Samet, 2003; 
Gorlova et al., 2007; Hackshaw et al., 1997; Shields and Harris, 2000). Several 
genetic aberrations have been found in human non-small cell lung cancer 
(NSCLC) including mutations in epidermal growth factor receptor (EGFR) and 
RAS, Loss of Heterozygosity (LOH) of TP53 and RB, and promoter 
hypermethylation of RARβ  (Burbee et al., 2001; Meuwissen and Berns, 2005; 
Sato et al., 2007; Virmani et al., 2000; Zochbauer-Muller et al., 2001). Some of 
these genetic changes have been proved to induce lung carcinogenesis in 
transgenic mice including mutant K-rasG12D (Guerra et al., 2003; Jackson et al., 
2001; Johnson et al., 2001; Tuveson et al., 2004) and mutant EGFR (Ohashi et 
al., 2008; Politi et al., 2006). Multiple signaling pathways including Akt, Erk and 
Stat3 are activated in mutant EGFR- and KrasG12D-induced lung tumors and 
deactivated during tumor regression suggesting these downstream signaling 
pathways are required to maintain tumor growth (Politi et al., 2006). Mutant 
EGFRs selectively promote cell survival by activating AKT and STAT signaling 
pathways but have no effect on proliferation (Sordella et al., 2004). 
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Treatment for lung cancer commonly includes surgery, chemotherapy, 
and radiation therapy. Non-small cell lung carcinoma is usually treated with 
cisplatin or carboplatin in combination with gemcitabine, paclitaxel, docetaxel, 
etoposide, or vinorelbine (Clegg et al., 2002). Cisplatin and etoposide are most 
commonly used to treat small cell lung carcinoma (Murray and Turrisi, 2006). 
Recently, the identification of molecular changes in lung tumors from never-
smokers has generated new therapeutic strategies for this disease 
(Subramanian and Govindan, 2010). Most NSCLC patients show no response 
to the EGFR tyrosine kinase inhibitor gefitinib, whereas about 10 percent of 
patients have a rapid and dramatic clinical response (Lynch et al., 2004). Higher 
response rates and better outcomes are seen when never-smoker patients with 
advanced NSCLC are treated with EGFR tyrosine kinase inhibitors such as 
gefitinib or erlotinib compared to the rates and outcomes of patients with 
tobacco-associated lung cancer (Miller et al., 2004; Shepherd et al., 2005; 
Subramanian and Govindan, 2007). This can be explained by the finding that 
activated EGFR mutants are present more frequently in lung tumors from never 
smokers compared with tobacco-associated lung cancer (Subramanian and 
Govindan, 2007). Further, activating mutations in EGFR are correlated with 
clinical response of non-small cell lung cancer to tyrosine kinase inhibitor 
gefitnib (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). Although non-
small cell lung cancer patients carrying EGFR-mutant have dramatic responses 
to EGFR inhibitors, patients may have a relapse, which is attribute to the 
presence of a second gefitinib resistance mutation or to the MET amplification 
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driving ERBB3-dependent activation of phosphoinositide 3-kinase (Engelman et 
al., 2007; Kobayashi et al., 2005). Although many cases of resistance are still 
undefined these data suggest that molecularly-targeted therapies using small 
molecules to inhibit the genetic aberrations, which tumor cells are addicted to 
will be an effective method to treat lung cancer patients (Linardou et al., 2009; 
Neal and Sequist, 2010).  Although some genetic changes are found in lung 
tumors from patients, many lung cancer patients do not show changes in these 
potential targets. Therefore, there is a need to identify new biomarkers for early 
diagnosis and novel targets for lung cancer prevention and therapy, which may 
decrease the high mortality of lung cancer. 
 
1.2 Signal Transducer and Activator of Transcription 3 (Stat3) 
 Stat3 is a member of the Stat protein family. Stat3 is a cytoplasmic 
transcription factor that is rapidly activated in response to various cytokines 
[e.g., interleukine 6 (IL-6), oncostatin M, interleukin 5 (IL-5), interleukin 11 (IL-
11), ciliary neurotrophic factor] and growth factors [e.g., epidermal growth factor 
(EGF)] that regulate cell proliferation, differentiation, survival, invasion, 
inflammation and immunity (Yu et al., 2009). For example, IL-6 and related 
cytokines bind to specific cell surface receptors that usually lack intrinsic 
tyrosine kinase activity but become associated through their cytoplasmic 
domain with tyrosine kinases such as the Janus kinase (JAK) family kinases 
(Yeh and Pellegrini, 1999). These kinases phosphorylate specific tyrosine 
residues in Stat proteins (e.g. Y705 in Stat3), leading to the formation of  
 - 6 -
(IL-6, LIF, OSM)
Bcl-XL, Cryab, Hspa1a, Mcl1
Vegf, Survivin, SOCS3
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Model for Stat3 signaling. Stat3 is a transcription factor, which is 
activated in response to many cytokines and growth factors that bind to specific 
receptors. In the case of the nontyrosine containing cytokine receptors, the JAK 
kinases are recruited to the receptor complex and phosphorylate the receptor 
on tyrosine. This phosphorylation leads to recruitment of Stat3 protein to the 
receptor/kinase complex through the SH2 domain of Stat3. Stat3 is then 
tyrosine phosphorylated at a single residue (tyrosine 705) in its C-terminus. 
Tyrosine phosphorylation of the Stat3 leads to Stat3 dimerization and nuclear 
translocation. In the nucleus Stat3 binds through its DNA-binding domain (DBD) 
to consensus elements, resulting in gene transcription. Adapted from 
(Pedranzini et al., 2004). 
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homodimers or heterodimers with other Stat proteins by reciprocal interactions 
through phosphotyrosine–SRC  homology 2 (SH2) domain then translocate into 
the nucleus and bind to consensus sequences in target genes to regulate gene 
transcription (Reich and Liu, 2006; Yu et al., 2009). In addition to specific 
tyrosine 705 phosphorylation, phosphorylation of Stat3 on serine 727 mediated 
by RSK2 is also required for maximal transcriptional activity of Stat3 (Decker 
and Kovarik, 2000; Wen et al., 1995; Zhang et al., 2003). Histone 
acetyltransferase p300-mediated Stat3 acetylation on Lys685 is important for 
Stat3 to form stable dimers, bind to DNA and regulate transcription of cell 
growth-related genes (Yuan et al., 2005). Activated Rac1 guanosine 
triphosphatase can form a complex with Stat3, which is critical for the Stat3 
activation induced by growth factors (Simon et al., 2000). Substitution of 2 
cysteine residues within the C-terminal loop of the SH2 domain of Stat3 
produced a molecule that dimerized spontaneously, bound to DNA, and 
activated transcription (Bromberg et al., 1999).   
 Stat3 is an acute phase response transcription factor and Stat3 signaling 
is well-controlled by several mechanisms. Suppressor of cytokine signaling 3 
(SOCS3), one of the Stat3 target genes, inhibits the activation of Stat3 through 
binding to the tyrosine kinase domain of JAK2 and serves as a negative 
feedback mediator of the Stat3 signaling (Masuhara et al., 1997). Protein 
inhibitor of activated Stat3 (PIAS3) blocks the DNA-binding activity of Stat3 and 
inhibits Stat3-mediated gene transcription by directly binding to Stat3 but did not 
interact with Stat1 nor affect its DNA-binding or transcriptional activity (Chung et 
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al., 1997). Stat3-beta is phosphorylated on tyrosine similar to Stat3 but co-
expression of Stat3-beta inhibits the transactivation potential of Stat3 
suggesting that Stat3-beta may function as a negative regulator of Stat3 
(Caldenhoven et al., 1996).   
 Stat3 is a transcription factor critical for TH17 differentiation and required 
for the suppression of pathogenic TH17 responses by CD4+ regulatory T cells 
[T (regs)] in mice (Chaudhry et al., 2009). Stat3 played a role in the cooperative 
signaling of BMP2 and LIF and the induction of astrocytes from neural 
progenitors by forming a complex with Smad1, which was bridged by p300 
(Nakashima et al., 1999). Dominant-negative mutations in Stat3 were found in 
the hyper-IgE syndrome, an immunodeficiency syndrome showing increased 
innate immune response and recurrent infections (Holland et al., 2007; 
Minegishi et al., 2007). Specific deletion of Stat3 under the control of the Nes 
promoter-enhancer limited the migration of reactive astrocytes and resulted in 
markedly widespread infiltration of inflammatory cells, and neural disruption 
indicating that Stat3 is a crucial regulator of reactive astrocytes in the process of 
healing after spinal cord injury (SCI) (Okada et al., 2006). Stat3 is activated in 
airway epithelial cells and is required for repair of normal airway epithelial cell 
after naphthalene injury (Kida et al., 2008). Cell-selective deletion of Stat3 in 
respiratory epithelial cells did not alter prenatal lung morphogenesis or 
postnatal lung function but made the Stat3Δ/Δ mice more susceptible to oxygen-
induced (exposure to 95% oxygen) injury than the wild type mice (Hokuto et al., 
2004), whereas activation of the Stat3 pathway prevents hyperoxia-induced 
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inflammation and injury in the lung (Lian et al., 2005), suggesting that Stat3 
plays important roles in preventing lung injury and in the repair process after 
lung injury. 
 It has also been shown that Stat3 can function as an oncogene and is 
frequently aberrantly activated in a variety of human solid tumor and blood 
malignancies including lung cancer, ovarian cancer, pancreatic cancer and 
lymphomas (Bromberg et al., 1999; Yu and Jove, 2004). Stat3 plays a critical 
role in both the initiation and the promotion stages of epithelial carcinogenesis. 
Mice with conditional knockout Stat3 in epidermal and follicular keratinocytes 
were completely resistant to DMBA-induced skin tumor development (Chan et 
al., 2004) indicating that Stat3 is required for the development of skin cancer 
induced by DMBA. Mice with specific Stat3 ablation in intestinal epithelial cells 
have reduced tumor growth and multiplicity indicating that Stat3 is required for 
the development of Colitis-Associated Cancer (Bollrath et al., 2009; Grivennikov 
et al., 2009). Inhibition of Stat3 by Stat3-beta, a dominant-negative variant, or 
Stat3 antisense in mouse tumor cell lines induced tumor-specific T-cell 
responses by upregulation of proinflammatory cytokines and chemokines that 
activate innate immunity and dendritic cells, which suggests that persistent 
activation of Stat3 suppressed the innate and adaptive antitumor immunity 
(Wang et al., 2004). Stat3 mediated constitutive NF-kappaB activity by 
enhancing NF-kappaB nuclear retention through acetyltransferase p300-
mediated RelA acetylation, which interfered with NF-kappaB nuclear export, in 
both cancer cells and tumor-associated hematopoietic cells (Lee et al., 2009). 
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Together with C/EBP-beta, Stat3 functioned as synergistic initiator and 
regulator of mesenchymal transformation in malignant glioma (Carro et al., 
2010). In addition to its nuclear transcriptional role, Stat3 was also located in 
the mitochondria and found to regulate metabolic function that supported Ras-
dependent malignant transformation (Gough et al., 2009; Wegrzyn et al., 2009). 
 More than 60% of lung cancers have been reported to possess 
constitutively activated STAT3 (Song et al., 2003). One possible explanation for 
this activation is that the suppressors of cytokine signaling 3 (Socs3), which is 
an endogenous natural inhibitor of Stat3 signaling, is frequently silenced by 
hypermethylation in human lung cancer (He et al., 2003). Increased Stat3 
activity regulates the expression of genes associated with wound healing and 
increased Stat3 activity is identified at the leading edge of lung tumors invading 
adjacent non-tumor stroma indicating that Stat3 is also important for tumor 
progression (Dauer et al., 2005).  It has been reported that the Stat3 signaling 
pathway is activated in mutant EGFR and KrasG12D-induced lung tumors (Politi 
et al., 2006). A previous study has shown that mutations in the EGFR kinase 
domain mediate STAT3 activation by increasing IL-6 levels in primary human 
lung adenocarcinomas (Gao et al., 2007). Furthermore, inhibiting STAT3 
function in fibroblasts abrogates transformation by mutant EGFR, indicating that 
STAT3 is required for the oncogenic effects of somatic EGFR mutations 
(Alvarez et al., 2006). Transgenic mice overexpressing constitutively activated 
Stat3 in alveolar type II epithelial cells exhibit severe pulmonary inflammation 
and develop spontaneous lung adenocarcinomas indicating that activating Stat3 
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in mouse lung is sufficient to induce these phenotypes (Li et al., 2007).  
 Since the JAK/STAT3 signaling pathway plays an important role in 
carcinogenesis, it has been targeted for cancer therapy (Costantino and 
Barlocco, 2008; Yu and Jove, 2004). For example, STAT3 activation can be 
suppressed by JAK inhibitors such as the tyrphostin AG 490 (Levitzki, 2002; 
Meydan et al., 1996) or AZD1480 (Hedvat et al., 2009), which induce apoptosis 
in cancer cells and inhibit tumor growth. Stat3 can also be targeted by inhibitors 
of its DNA-binding activity such as G-quartet oligonucleotides, which were 
found to promote apoptosis of non-small cell lung cancer (Weerasinghe et al., 
2007).  
 
1.3 LIF-LIFR/GP130-STAT3 Signaling 
Leukemia inhibitory factor (LIF) is one of the IL-6 family cytokines 
including ciliary neurotrophic factor (CNTF), oncostatin M, interleukin 11 (IL-11) 
and interleukin 6 (IL-6). The function of these cytokines is mediated by specific 
cell-surface receptors that have a unique α chain and the shared signal 
transducer GP130 (Taga and Kishimoto, 1997). Activation of these receptors 
induces activation of the JAK family tyrosine kinases, which then stimulate 
multiple signaling pathways involving MAPKs, PI3Ks and STATs (Hong et al., 
2007). LIF induces macrophage differentiation of the murine M1 myeloid 
leukaemia cell line indicating that it functions as a leukemia inhibitor (Gearing et 
al., 1987; Gough et al., 1988). LIF is also a human hemopoietic growth factor 
and maintains the proliferation of the murine interleukin-3-dependent leukemic 
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cell line suggesting it has both growth-promoting and differentiation-inducing 
activities depending on the target cell type (Moreau et al., 1988). LIF serves as 
a growth factor for the maintenance of the stem-cell phenotype of mouse 
embryonic stem (ES) cells in vitro, which have the potential to form chimaeric 
mice (Williams et al., 1988). The ureteric bud cells express and secrete LIF, and 
metanephric mesenchyme express its receptors, suggesting that LIF is a 
potential regulator of mesenchymal-to-epithelial transition during kidney 
development (Barasch et al., 1999). LIF is a pleiotropic cytokine present at the 
maternal-fetal interface and has been shown to play an essential role in the 
implantation of the embryo in mice (Escary et al., 1993; Stewart et al., 1992). 
Human leukocyte antigen type G (HLA-G) is a class I MHC molecule 
specifically expressed by human invasive cytotrophoblast cells and has been 
suggested to play a role in facilitating the immune tolerance of the conceptus 
(Aldrich et al., 2001; Hviid et al., 2003; Ober et al., 2003; Pfeiffer et al., 2001). 
LIF induced the expression of HLA-G mRNA and activated the HLA-G promoter 
indicating that LIF may play an important role in modulating HLA-G production 
and immune tolerance of conceptus at the maternal-fetal interface (Bamberger 
et al., 2000). LIF was also identified as a p53-regulated gene that functions as 
the downstream mediator of impaired implantation in female p53-null mice (Hu 
et al., 2007).  
IL-6 family members were significantly increased in the lung and induced 
activation of Stat3 during E. coli pneumonia, which functions to promote 
neutrophil recruitment and to limit lung infection and injury (Quinton et al., 2008). 
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Transgenic mice with pulmonary expression of human LIF are more resistant to 
hyperoxia induced lung injury and LIF transgenic mice with IL-6 null mutation 
were more sensitive to the toxic effects of 100% O2 than LIF-transgenic animals 
with a wild-type IL-6 indicating that LIF plays a protective role in hyperoxic acute 
lung injury partly through increasing the expression of IL-6 (Wang et al., 2003). 
The major source of LIF in human lung tissue is airway fibroblasts and airway 
smooth muscle cells, which indicate that LIF and other family cytokines play 
roles in the proliferative response of both epithelial and mesenchymal cells 
(Knight, 2001; Knight et al., 1999).  
Smad-dependent induction of LIF in response to TGF-beta is required for 
the self-renewal capacity of Glioma-initiating cells (GICs) and prevents their 
differentiation which may be important for the initiation and recurrence of 
gliomas (Penuelas et al., 2009). IL-6 is an important activator of oncogenic 
STAT3 in lung adenocarcinomas and of Jagged-1/Notch signaling in breast 
tumor mammospheres (Grivennikov and Karin, 2008; Schafer and Brugge, 
2007). LIF has been reported to act as an autocrine growth factor in human 
medulloblastomas, breast cancer, and pancreas carcinoma (Dhingra et al., 
1998; Kamohara et al., 2007; Liu et al., 1999; Quaglino et al., 2007). LIF is a 
potential metastasis-promoting factor for melanoma and rhabdomyosarcomas 
(Maruta et al., 2009; Wysoczynski et al., 2007). It has been described that 
transformation of human bronchial epithelial cells increases the activation of 
STAT3 induced by LIF suggesting that altered cytokine responses may be an 
early event in primary premalignant cells and may play critical role in lung 
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tumorigenesis (Loewen et al., 2005). LIF mRNA was detected in some human 
lung cancer cell lines and LIF protein was found in the conditioned medium of 
human lung cancer cells (Kamohara et al., 1994) and human lung cancer 
xenografts (Kamoshida et al., 2006), suggesting that LIF may also be  a growth 
factor in human lung cancer.  
 
1.4 GPRC5A as a New Lung Tumor Suppressor 
G protein-coupled receptor, family C, group 5, member A (GPRC5A) was 
cloned as a retinoic acid induced gene in UMSCC22B cells by differential 
display (Cheng and Lotan, 1998). GPRC5A is a protein with seven trans-
membrane domains and is located mainly in the cell plasma membrane and 
perinuclear vesicles (Fig. 3). GPRC5A is an orphan receptor because the 
identity of its ligand is not known yet. In addition, it is not clear whether 
GPRC5A is activated by ligand binding or is constitutively activated by other 
mechanisms (Seifert and Wenzel-Seifert, 2002). The reason for this question is 
that the GPRC5A protein has a short (about 30 amino acids) extracellular 
amino terminal domain (ATD), whereas other members of the GPCR family C 
such as the glutamate receptor (mGluR1) and the calcium sensing receptor 
(CaR) have long ATDs (about 600 amino acids), which include their ligand-
binding cleft (Brauner-Osborne et al., 2001). GPRC5A binds to frizzled 
receptors and may crosstalk and activate the non-canonical Wnt signaling 
pathway (Harada et al., 2007). GPRC5A was also involved in regulating the 
cAMP signaling and apoptosis (Hirano et al., 2006). GPRC5A was primarily and 
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abundantly expressed in human fetal and adult lung tissue and restricted to 
distal bronchiolar epithelial cells in postnatal lungs (Cheng and Lotan, 1998; Xu 
et al., 2005), which indicated that it might play important role in lung 
physiological and pathological function.  
The expression of GPRC5A was suppressed in some human lung 
cancer cell lines and human non-small cell lung cancer when compared with the 
normal tissue from the same patient (Cheng and Lotan, 1998; Tao et al., 2007). 
In the absence of information on its activation mechanism, we attempted to gain 
some insight into the actions GPRC5A by restoration of its expression into 
tumor cells via transfection. Overexpression GPRC5A in H1792, and 293F cells 
decreased the anchorage-independent colony formation (Tao et al., 2007). The 
inhibition of anchorage-independent colony formation by expression GPRC5A 
in human lung cancer cells indicated that it may play a role in regulating cell 
survival and the transformed cell phenotype (Tao et al., 2007) and suggested 
that GPRC5A may function as a putative tumor suppressor in the lung. 
Controversially, other group reported that GPRC5A was a growth-promoting 
gene and a therapeutic target for breast cancer (Nagahata et al., 2005; Wu et 
al., 2005). To further confirm our hypothesis, we generated Gprc5a knockout 
mice; these mice do not have lung developmental defects (Tao et al., 2007). 
Another group has reported the similar result (Xu et al., 2005). Interestingly, we 
found that homozygous Gprc5a knockout (Gprc5a-/-) mice spontaneously 
developed many more lung tumors at an advanced age (incidence:  
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Figure 3. Schema of GPRC5A protein. GPRC5A is a protein with seven 
transmembrane domains. It has an N-glycosylation site at residue 158 and 8 
potential phosphorylation sites predicted by using NetPhos 2.0 webtool 
(http://www.cbs.dtu.dk/services/NetPhos/). 
 
 - 17 -
A B
 
 
 
 
Figure 4. Gprc5a functions as a new lung tumor suppressor. A, The expression 
of Gprc5a protein was analyzed by immunohiostochemical methods in sections 
of lung tissues from adult Gprc5a+/+ or Gprc5a-/- mice. B, Mice were killed 
between the ages of 10 and 24 months, and tumors were detected by visual 
inspection of the lung exterior after necropsy. P values (calculated using a two-
sided z test) at the bottom of the panel indicate the statistical signifi cance of 
difference in tumor incidence in Gprc5a+/- and Gprc5a-/- mice compared with 
Gprc5a+/+ mice (Tao et al., 2007). 
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76% adenomas and 17% adenocarcinomas) than wild type (Gprc5a+/+) (10% 
adenomas) (Fig. 4), which strongly indicated that Gprc5a functions as a tumor 
suppressor in mouse lung (Tao et al., 2007). 40% Gprc5a deficient mice 
developed pneumonia compared with 10% wild type group suggested that there 
are more inflammation in the Gprc5a knockout mice (Tao et al., 2007). Recently 
we reported that NF-kappaB activation was increased in Gprc5a-/- lung epithelial 
cells, which leads to increased autocrine and paracrine interactions, cell 
autonomy, and lung inflammation (Deng et al., 2010). 
 
1.5 Hypothesis and project goals 
Previous studies have led to the conclusion that GPRC5A is a new lung 
specific tumor suppressor gene based on the following evidence: 1) GPRC5A is 
primarily and abundantly expressed in normal lung epithelial cells but its 
expression is decreased in human lung cancer cell lines and in human lung 
tumor tissues from patients. 2) Gprc5a-/- mice spontaneously developed many 
more lung adenomas and adenocarcinomas at advanced age than Gprc5a+/+ 
mice. However, the mechanism(s) by which GPRC5A inhibits lung 
carcinogenesis are still not clear. It is worthy to determine these mechanisms 
because they may help us find new targets for lung cancer therapy and 
prevention to reduce the high mortality of lung cancer. Since Stat3 is an 
oncogene and the activation of Stat3 has been reported to occur in the majority 
of lung cancers, we hypothesize that loss of Gprc5a causes deregulated Stat3 
signaling leading to gain of the transformed phenotypes, which contributes to 
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lung tumorigenesis in Gprc5a-/- mice.  The objectives of my thesis research are 
to understand the importance of Stat3 signaling in lung carcinogenesis in 
Gprc5a-/- mice and the mechanisms by which loss of Gprc5a increases Stat3 
activity.  
First, we will find the differences between Gprc5a+/+ and Gprc5a-/- normal 
airway epithelial cells isolated from tracheas of Gprc5a+/+ and Gprc5a-/- mice. 
We will examine whether Gprc5a-/- normal airway epithelial cells present some 
of the transformed phenotypes like resistant to apoptosis and increased 
anchorage-independent growth. We will analyze the gene expression pattern 
using microarray and examine whether Stat3 signaling is deregulated and Stat3 
targeted genes will differentially expressed between Gprc5a+/+ and Gprc5a-/- 
normal airway epithelial cells, which may contribute to the transformed 
phenotype. Quantitive Realtime PCR and western blotting assays will be 
applied to verify the microarray data and deregulated signaling pathway. Stat3 
activation will be determined by analyzing the tyrosine phosphorylation of Stat3 
using western blotting in Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells. 
 Second, we will determine the mechanisms by which loss of Gprc5a 
increases Stat3 activity. We will examine whether Stat3 activation is induced by 
EGFR signaling since the culture medium contains EGF or by autocrine 
cytokine signaling. To examine whether Gprc5a+/+ and Gprc5a-/- normal airway 
epithelial cells have different response to EGF leading to the different activation 
of Stat3, cells will be treated with EGF and analyzed for Stat3 activity. JAK 
inhibitors (AG490) will be used to examine whether Stat3 activity is induced by 
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the cytokines if Stat3 activation is not dependent on the EGFR signaling. 
Gprc5a-/- normal airway epithelial cells will be cultured in medium without any 
supplements to determine whether Stat3 activity is induced by autocrine Stat3 
activator(s). We will determine whether different activation of Stat3 is due to 
different level of Stat3 activator(s) in the conditioned medium from Gprc5a+/+ 
and Gprc5a-/- normal airway epithelial cells or due to the different response to 
the Stat3 activator(s) in the conditioned medium. Neutralizing antibodies against 
different cytokines will be used to identify the Stat3 activator(s) in the 
conditioned medium of Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells.  
We will determine the mechanisms leading to the different level of Stat3 
activator(s) in the conditioned medium from Gprc5a+/+ and Gprc5a-/- normal 
airway epithelial cells or the different response to the Stat3 activator(s). We will 
examine whether MDA959 tumor cells also have increased Stat3 activity and 
whether this activation is due to the same mechanism as Gprc5a-/- normal 
airway epithelial cells. 
 Finally, we will determine whether Stat3 activation is important for the 
transformed phenotypes of Gprc5a-/- normal airway epithelial cells and MDA959 
tumor cells. Gprc5a-/- normal airway epithelial cells and MDA959 tumor cells will 
be transfected with dominant negative Stat3 construct (Y705F) to inhibit the 
activity of Stat3. The effect of inhibition Stat3 by the dominant negative Stat3 on 
the transformed phenotypes (apoptosis and anchorage independent growth) will 
be assayed. Gprc5a-/- normal airway epithelial cells and MDA959 tumor cells 
will also be treated with AG490, a JAK inhibitor, and effect of inhibition Stat3 
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AG490 on the transformed phenotypes (apoptosis and anchorage independent 
growth) will be assayed. 
 These studies will provide part of the mechanisms by which GPRC5A 
suppress lung tumorigenesis and Stat3 may play a critical role in the 
development of lung tumors in Gprc5a-/- mice. This mouse model may be a 
useful tool for chemoprevention study and for studies for Stat3 inhibitors in vivo. 
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CHAPTER 2 MATERIALS AND METHODS 
 
2.1 Cell lines and culture conditions 
Epithelial cells were derived from normal tracheas of three week old 
Gprc5a-/- and Gprc5a+/+ mice (C57Bl/6 x 129sv) F1 and from a spontaneous 
lung adenocarcinoma from a Gprc5a-/- mouse. Briefly, tracheas and tumor 
tissue were dissected from mice, cut into small fragments, and incubated in a 
tissue dissociating solution ACCUMAX (Innovative Cell Technologies, San 
Diego, CA). The dissociated cells and tissue fragments were then transferred to 
PRIMARIA tissue culture dishes (BD Biosciences, San Jose, CA) and incubated 
in AmnioMAX-C100 medium (Invitrogen, Carlsbad, CA). The epithelial cells that 
have grown in these dishes were detached by trypsinization, sub-cultured and 
grown in keratinocyte-serum-free medium (K-SFM) (GIBCO; Invitrogen, Grand 
Island, NY). The cell lines were karyotyped by G banding in the Institutional 
Molecular Cytogenetics Facility (MD Anderson Cancer center, Houston, TX) 
and found to be of mouse origin. The cells were expanded and numerous 
aliquots of low passage (5 to 8) were frozen in liquid nitrogen and thawed 
before use for up to three months. The normal epithelial cells were cultured in 
K-SFM supplemented with epidermal growth factor (EGF) and bovine pituitary 
extract (BPE) (GIBCO, Invitrogen) and the tumor cells were cultured in 
Dulbecco’s modification of Eagles medium (DMEM) and Ham’s F12 medium 
(1:1) supplemented with 10% fetal bovine serum. 293T cells were cultured in 
Dulbecco’s modification of Eagles medium (DMEM) and Ham’s F12 medium 
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(1:1) supplemented with 10% fetal bovine serum. 
 
2.2 Reagents and antibodies 
AG490 was purchased from EMD Chemicals (Gibbstown, NJ). 
Antibodies against pStat3(Y705), Stat3, pErk1/2, Erk1/2, Bcl-XL and Socs3 
were purchased from Cell Signaling Technology (Danvers, MA). Mcl-1 antibody 
was purchased from Epitomics (Burlingame, CA). Hspa1a and Cryab antibodies 
were purchased from Assay Designs (Ann Arbor, MI). Flag antibody to detect 
expression of transfected flag-tagged dominant negative Stat3 was purchased 
from Sigma (St. Louis, MO). Neutralizing antibodies against mouse Lif, Il-6, 
Osm and normal goat IgG were purchased from R&D Systems (Minneapolis, 
MN). ESGRO® (LIF) was purchased from Millipore (Billerica, MA). EGF was 
purchased from Invitrogen. 
 
2.3 Plasmid construction 
GPRC5A open reading frame was cloned by PCR from cDNA of 292G 
human lung carcinoma cell line using primers RAI3-F containing KpnI site 
(Italic) (GCAC GGTACC GCCACC ATG GCT ACA ACA GTC CCT GAT GGT 
TGC CGC AAT) and RAI3-R containing XbaI site (Italic) (GAGC TCTAGA CTA 
GCT GCC CTC TTT CTT TAC TTC ATA GTC TTT) and subcloned into 
pcDNA3.1(+) plasmid. To construct the pcDNA3.1(+)-GPRC5A-Myc plasmid,  
GPRC5A coding sequence with myc tag at its C-terminal was generated by 
PCR using primers RAI3-F and RAI3-Myc containing myc tag (underline) and 
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XbaI site (Italic) (GAGC TCTAGA CTA CAG ATC CTC TTC AGA GAT GAG 
TTT CTG CTC GCT GCC CTC TTT CTT TAC TTC ATA GTC TTT) and 
subcloned into pcDNA3.1(+) plasmid. To generate the pAcGFP1-Hyg-N1-
GPRC5A plasmid, GPRC5A coding sequence was generated by PCR using 
primers RAI3-F and  RAI3-R2 containing AgeI site (Italic) (GAGC ACCGG TGG 
GCT GCC CTC TTT CTT TAC TTC ATA GTC TTT) and subcloned in frame into 
pAcGFP1-Hyg-N1 plasmid (from Clontech). pCMV6-Entry-SOCS3 plasmid was 
purchased from Origene (Rockville, MD). To generate the pCMV-3Tag-8-
SOCS3 plasmid expressing a flag tagged SOCS3 protein, the SOCS3 cDNA 
was released from pCMV6-Entry-SOCS3 plasmid by digested with BamHI and 
XhoI and subcloned into the pCMV-3Tag-8 plasmid. To generate the pDsred-
Monomer-N1-SOCS3 plasmid, the SOCS3 coding sequence was generated by 
PCR using SOCS3 template released from pCMV-3Tag-8-SOCS3 plasmid and 
the primers hSOCS3-F containing XhoI site (Italic) (GCAC CTCGAG GCCACC 
ATG GTC ACC CAC AGC AAG TTT CCC GCC GCC) and hSOCS3-R2 
containing EcoRI site (Italic) (GAGC G AAT TCG AAG CGG GGC ATC GTA 
CTG GTC CAG GAA CTC), then subcloned in frame into the pDsRed-
Monomer-N1 plasmid (from Clontech). A plasmid containing mutant 
Stat3(Y705F) with flag tag generated in Dr. James E. Darnell, Jr’s laboratory 
(The Rockefeller University, New York, NY) (Bromberg et al., 1998; Wen and 
Darnell, 1997) was purchased from Addgene (plasmid 8709). The plasmid 
pRc/CMV-Stat3(Y705F) was digested using SacI to release the Stat3(Y705F)-
Flag cDNA, which was then subcloned into pIRES2-EGFP as an intermediate 
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step before releasing Stat3(Y705F)-Flag cDNA by digestion of pIRES2-EGFP-
Stat3(Y705F)-Flag using BamHI and subcloning it into pIREShyg3 to generate 
pIREShyg3-Stat3(Y705F)-Flag expression vector.  
 
2.4 Transfection reagent and stable transfected cells 
All transfections were done by using Fugene 6 transfection reagent 
purchased from Roche (Madison, WI). To generate stable cell line, Gprc5a-/- 
cells were transfected with pIREShyg3 or pIREShyg3-Stat3(Y705F)-Flag 
expression vector. After 48 hours, stably transected cells were selected by 
adding hygromycin at 500 μg/ml (Clontech, Mountain View, CA) and cultured for 
2 weeks. 
 
2.5 Immunoblotting 
Cells were washed with PBS then lysed using the cell lysis buffer (Cell 
Signaling Technology) following the procedure described in manufacturer’s 
protocol. Equal amounts of cell extract protein (20 μg) were resolved by sodium 
dodecyl sulfate (SDS)–polyacrylamide gels (10%) and transferred to a 
nitrocellulose membrane. After blocking with 5% (w/v) powdered non-fat milk in 
Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBST), the membrane 
was incubated with first antibody diluted in 5% (w/v) Bovine Serum Albumin 
(BSA) solution in TBST at 4°C overnight. The membrane was washed three 
times (5 minutes each) with TBST and incubated with appropriate secondary 
antibody for 1 hour at room temperature. The membrane was washed three 
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times and detection of protein–antibody complexes was done by using 
SuperSignal West Pico Chemiluminescent Substrate from Thermo Fisher 
Scientific (Rockford, IL) and exposure to X-ray film. The signal strengths were 
quantitated by densitometric analysis using Quantity One software. 
 
2.6 Immunoprecipitation (IP) assay 
 Human embryonic kidney cell line 293T cells were transfected with the 
expression plasmids for GPRC5A and SOCS3. After 48 hours culture, the cells 
were washed with PBS and harvested using the cell lysis buffer (Cell Signaling 
Technology). The cell lysates were pre-cleared by incubating with protein G 
beads and mouse normal IgG control for 1 hour at 4°C. Then the lysates were 
immunoprecipitated by incubating them with anti-flag antibody or mouse normal 
IgG at 4°C overnight, then added protein G beads and incubated them at 4°C 
for one more hour. The beads were washed 5 times with PBS and protein 
complexes were released from the beads by adding SDS loading buffer and 
boiling for 10 minutes. The proteins were subjected to western blotting analysis.  
 
2.7 Enzyme-linked immunosorbent assay 
Conditioned media from Gprc5a+/+ and Gprc5a-/- cells were harvested by 
centrifugation at 13000 rpm/min for 10 minutes and analyzed for the level of Lif 
by using Mouse LIF Quantikine ELISA Kit from R&D Systems following the 
manufacturer’s protocol.  
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2.8 RNA extraction and real-time quantitative PCR 
Total RNA was extracted from Gprc5a+/+ and Gprc5a-/- normal tracheal 
epithelial cells using TRI Reagent from Molecular Research Center (Cincinnati, 
OH) according to the manufacturer's protocol. For reverse transcription (RT) 
reaction, 0.5 μg of total RNA of each sample was reverse transcribed into cDNA 
using RETROscript® Kit from A&B Applied Biosystems (Austin, TX) according 
to the manufacturer’s instructions. Each cDNA was diluted 50 fold using 
UltraPure™ DNase/RNase-Free Distilled Water from Invitrogen for Quantitative 
real-time PCR reaction (QPCR). The primers for QPCR and TaqMan Gene 
Expression Master Mix were purchased from A&B Applied Biosystems. Mouse 
Actin was used as an internal control gene. In real time PCR, samples were 
denatured at 95°C for 10 minutes and 40 cycles were performed at 95°C for 15 
seconds and at 60°C for 1 minute using Applied Biosystems 7500 Fast Real-
Time PCR System. The expression data was analyzed and normalized to actin 
using the 7500 Fast System Software. 
 
2.9 Anchorage-independent growth assay 
Cells were suspended in 0.2 ml of Matrigel (Collaborative Biomedical 
Products, Becton Dickinson Labware) diluted 1:1 (vol/vol) with growth medium. 
The mixture was then placed on top of 0.2 ml of semisolid 1% agarose in 
growth medium in each well of a 24-well cluster plate and incubated for 2 weeks. 
All the experiments were performed using triplicate wells. After 2 weeks, the 
total number of colonies (defined as >50 cells) in each well was counted under 
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an inverted microscope at X 40 magnification and photographed with a digital 
camera. The mean ± SD of the number of colonies per well was calculated. 
 
2.10 Apoptosis assay 
Apoptosis was measured by using FITC-Annexin V Apoptosis Detection 
Kit from BD Biosciences (San Jose, CA). Apoptosis was induced by starving 
cells in K-SFM medium without EGF and BPE for 48 hours. Cells were then 
washed twice with cold PBS and resuspended in 1X Binding buffer, then 
stained with FITC-Annexin V and PI (propidium Iodide) for 15 minutes at room 
temperature in the dark and analyzed by flow cytometry. The assays were 
performed in triplicates and the mean ± SD were calculated.   
 
2.11 Statistical analyses 
All analyses were performed in triplicates and the significance of 
differences between groups was calculated using the student’s t test.  P value 
<0.05 was considered to be statistically significant. 
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CHAPTER 3 ISOLATION AND CHARACTERIZATION OF GPRC5A+/+ AND 
GPRC5A-/- NORMAL AIRWAY EPITHELIAL CELLS 
 
3.1 Isolation of the Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells 
We have previously shown that Gprc5a-/- mice spontaneously develop 
lung adenoma and adenocarcinoma at an advanced age (Tao et al., 2007), 
which is similar to the process of human lung cancer development. However, 
the mechanisms by which GPRC5A suppresses lung tumor development are 
still unclear. To elucidate the mechanisms of GPRC5A lung tumor suppressor 
function, we established normal airway epithelial cell lines isolated from the 
tracheas of three week old Gprc5a+/+ and Gprc5a-/- mice. These Gprc5a+/+ and 
Gprc5a-/- normal airway epithelial cells grew well in vitro and showed epithelial 
morphology. To confirm that Gprc5a was deleted in Gprc5a-/- normal airway 
epithelial cells, we harvested RNA and proteins from Gprc5a+/+ and Gprc5a-/- 
cells cultured in K-SFM supplemented with EGF and BPE for 48 hours, and 
analyzed them for the expression level of Gprc5a mRNA and protein. As shown 
in Figure. 5A and 5B, both mRNA and protein of Gprc5a were absent in Gprc5a-
/- cells compared to Gprc5a+/+ cells indicating that the cells exhibited the 
expected phenotypes.    
 
3.2 Gprc5a-/- cells were resistant to starvation-induced apoptosis 
compared to Gprc5a+/+ cells 
Malignant transformation of cells usually involves increased survival 
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Figure 5. Characteristics of Gprc5a+/+ and Gprc5a-/- normal airway epithelial 
cells. A, Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells were cultured in 
K-SFM supplemented with EGF and BPE for 48 hours, then cells were 
extracted for RNA and analyzed for Gprc5a mRNA levels using QPCR. B, Cells 
cultured as in A were extracted for protein and analyzed for Gprc5a protein 
levels using western blotting. 
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signaling and resistance to apoptosis (Hanahan and Weinberg, 2000). 
Therefore, we compared the apoptosis of Gprc5a+/+ and Gprc5a-/- normal airway 
epithelial cells under starvation. We observed that Gprc5a-/- cells had 
decreased apoptosis relative to Gprc5a+/+ cells when starved for 48 hours in K-
SFM without supplements (Fig. 6A). Specifically, starvation induced 22.9% cell 
death in Gprc5a+/+ cells but only 9.1% in Gprc5a-/- cells (Fig. 6B) indicating that 
loss of Gprc5a resulted in increased cell survival.  
 
3.3 Gprc5a-/- cells exhibited increased colony formation ability in Matrigel 
compared to Gprc5a+/+ cells 
Next, we compared the ability of Gprc5a+/+ and Gprc5a-/- cells to form colonies 
in semi-solid medium, an important property of transformed and tumor cells 
(Tucker et al., 1977). Since they were isolated from the normal tracheas, both 
Gprc5a+/+ and Gprc5a-/- cells were not expected to form colonies in agar or 
agarose and indeed they failed to do so (data not shown). However, we found 
that Gprc5a-/- cells formed many more colonies than Gprc5a+/+ cells when 
cultured in suspension in Matrigel (Fig. 7A). Gprc5a-/- cells formed about 40 
colonies whereas Gprc5a+/+ cells formed rare colonies (Fig. 7B). The increased 
anchorage-independent growth of Gprc5a-/- cells indicates that loss of Gprc5a 
tumor suppressor in normal airway epithelial cells caused acquisition of 
transformed phenotypes which are important for tumorigenesis.  
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Figure 6. Gprc5a-/- normal airway epithelial cells are more resistant to starvation 
induced apoptosis compared to Gprc5a+/+ cells. A, Gprc5a+/+ and Gprc5a-/- 
normal airway epithelial cells were cultured in K-SFM without supplements for 
48 hours, then cells were double staining with PI and AnnV-FITC and then 
analyzed  for apoptosis by flow cytometry. Results of one of the triplicates is 
presented. B, the mean ± SD of three independent experiments in panel A was 
shown in bar graph. P value were calculated using Student T-test and * means 
P < 0.05.   
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Figure 7. Gprc5a-/- normal airway epithelial cells exhibit anchorage independent 
growth ability. A, Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells were 
suspended in Matrigel and cultured for two weeks to assay the colony formation. 
Photomicrographs of cultures at high magnification of one experiment were 
showed. B, colonies in three wells (each cell line) in panel A were counted and 
the data are presented in bar graph as mean ± SD colonies/well. P value were 
calculated using Student T-test and * means P < 0.05.   
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3.4 Stat3 signaling is deregulated in Gprc5a-/- normal airway epithelial 
cells 
 To investigate the difference in signal transduction pathways between 
Gprc5a+/+ and Gprc5a-/- cells, we analyzed the transcription profiles of Gprc5a+/+ 
and Gprc5a-/- cells using microarray and the signaling pathway using Ingenuity 
Pathway Analysis. We observed that many genes in the Stat3 pathway were 
differentially expressed between Gprc5a+/+ and Gprc5a-/- cells (Fig. 8). Among 
these changed genes, we found that leukemia inhibitory factor (Lif), an IL-6 
family member and upstream activator of Stat3 signaling, was increased in 
Gprc5a-/- cells compared to Gprc5a+/+ cells (Fig. 8). Moreover, several anti-
apoptotic genes which are Stat3 targets including Bcl-XL, Cryab, Hspa1a, and 
Mcl1 were upregulated in Gprc5a-/- cells relative to Gprc5a+/+ cells (Fig. 8), 
which may explain the resistance to starvation induced apoptosis and increased 
colony formation of Gprc5a-/- cells.  
 
3.5 Increased expression of anti-apoptotic genes in Gprc5a-/- normal 
airway epithelial cells compared to Gprc5a+/+ cells 
 To further confirm that Stat3 regulated anti-apoptotic genes were 
upregulated in Gprc5a-/- cells compared to Gprc5a+/+ cells, we analyzed the 
mRNA and protein levels of Bcl-XL, Cryab, Hspa1a and Mcl1 in Gprc5a+/+ and 
Gprc5a-/- cells cultured in K-SFM medium supplemented with EGF and BPE  for 
48 hours. We found that the mRNA levels of these genes were significantly 
increased in Gprc5a-/- cells when compared to Gprc5a+/+ cells (Fig. 9A). We  
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Figure 8. Deregulated Stat3 pathway in Gprc5a-/- normal airway epithelial cells 
compared to Gprc5a+/+ normal airway epithelial cells. Gprc5a+/+ and Gprc5a-/- 
normal airway epithelial cells were cultured in K-SFM supplemented with EGF 
and BPE for 48 hours, then cells were extracted for RNA and analyzed using 
and Affymetrix microarray. The fold changes were calculated and Stat3 
pathway analysis was done using Ingenuity Pathway Analysis (IPA).   
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Figure 9. Increased expression of Stat3 regulated anti-apoptotic genes in 
Gprc5a-/- normal airway epithelial cells relative to Gprc5a+/+ cells. A, Gprc5a+/+ 
and Gprc5a-/- normal airway epithelial cells were cultured in K-SFM without 
supplements for 48 hours, then RNA was extracted from the cells and analyzed 
for levels of Stat3 targeted genes by QPCR. *, P < 0.05. B, Gprc5a+/+ and 
Gprc5a-/- normal airway epithelial cells were cultured in K-SFM without 
supplements for 48 hours, then cells were extracted for protein and analyzed 
protein levels of Stat3 targeted genes by western blotting. 
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also observed that there Gprc5a-/- cells contained more Bcl-XL, Cryab, Hspa1a 
and Mcl1 proteins than Gprc5a+/+ cells (Fig. 9B).  
 
3.6 Discussion 
 In this thesis, we plan to explore the potential mechanisms by which the 
orphan G protein coupled receptor Gprc5a functions as a tumor suppressor in 
mouse lung in vivo.  We isolated and established normal airway epithelial cell 
lines from tracheas of very young (3-week old) wild type mice (Gprc5a+/+) and 
knockout mice (Gprc5a-/-) after we found that mice with knockout of this gene 
develop lung adenomas and adenocarcinomas spontaneously (Tao et al., 2007). 
These cell lines will be very useful and suitable tools to study the lung-specific 
tumor suppressor function of Gprc5a. First, they were isolated from the airway 
epithelial cells where mouse lung tumors derived from so that they would be 
better than Mouse Embryonic Fibroblast (MEF) cells from these mice. Second, 
these cells were isolated from the normal airway of very young mice (only 3 
weeks old) when no lung tumors developed, thus they may help us to find early 
biochemical and biological changes in the initiation stage of lung tumorigenesis 
in Gprc5a-/- mice. 
The characterization of these cells as described here revealed that 
Gprc5a-/- normal airway epithelial cells isolated from normal trachea of a young 
mouse exhibited resistance to starvation-induced apoptosis and ability to form 
colonies in semi-solid medium, both of which are features associated with cell 
transformation (Hanahan and Weinberg, 2000). In contrast, Gprc5a+/+ cells 
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were more sensitive to starvation-induced apoptosis than the Gprc5a-/- cells and 
failed to grow in semi-solid medium. However, the Gprc5a-/- cells are non-
tumorigenic. Thus, our findings demonstrate that the Gprc5a-/- cells exhibit 
properties associated with the transformed cell phenotype but not the 
tumorigenic phenotype and therefore, they may be considered premalignant 
cells (Hanahan and Weinberg, 2000; Tucker et al., 1977). It is important to note 
that the acquisition of the malignant (tumorigenic) phenotype by cultured 
epithelial cells may require multiple genetic and epigenetic changes. For 
example human bronchial epithelial cells immortalized by overexpression of the 
human telomerase reverse transcriptase, transfection of CDK4 to bypass the 
p16/RB pathway, silencing the p53 pathway and introduction of mutant K-
RASV12 or mutant EGFR, were able to form colonies in semi-solid medium but 
were still unable to form tumors in immunodeficient mice (Sato et al., 2006). 
 The finding that Stat3 signaling pathway was deregulated in Gprc5a-/- 
cells by the transcription profile analysis using microarray data and Ingenuity 
Pathway Analysis was really interesting since Stat3 is a well known oncogene 
and related to tumorigenesis (Bromberg et al., 1999). Bcl-XL has been reported 
to regulate cell apoptosis and promote cell survival through controlling the 
electrical and osmotic homeostasis of mitochondria (Boise et al., 1993; Vander 
Heiden et al., 1997). Cryab is a member of the small heat-shock protein family 
and inhibited caspase-3 activation during myogenic differentiation leading to 
decreased apoptosis (Dubin et al., 1990; Kamradt et al., 2002). Hspa1a is a 
negative regulator of apoptosis through directly binding to ASK1 and inhibiting 
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ASK1-dependent apoptosis (Park et al., 2002). Mcl1 is a potent multidomain 
antiapoptotic protein of the BCL2 family that heterodimerizes with other BCL2 
family members to protect against apoptosis (Mott et al., 2007). The 
upregulation of these Stat3-regulated anti-apoptotic genes at both the mRNA 
and protein levels in the Gprc5a-/- cells compared to Gprc5a+/+ cells suggested 
that Stat3 may be more activated in the Gprc5a-/- cells than in the Gprc5a+/+ 
cells, which may contribute to the resistant to apoptosis and increased colony 
formation of Gprc5a-/- cells and the lung tumorigenesis in Gprc5a-/- mice. These 
observations are based on isolated Gprc5a+/+ and Gprc5a-/- cells cultured in 
vitro and it will be worthy to look in vivo data by analyzing the mRNA and 
protein levels of these Stat3 regulated anti-apoptotic genes in lung tissues from 
Gprc5a+/+ and Gprc5a-/- mice. 
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CHAPTER 4 AUTOCRINE LIF INDUCED STAT3 ACTIVATION LEADS TO 
THE TRANSFORMED PHENOTYPES IN GPRC5A-/- CELLS AND MDA959 
LUNG TUMOR CELLS 
 
4.1 Higher Stat3 activation in Gprc5a-/- normal airway epithelial cells 
compared to Gprc5a+/+ cells 
 Since we found that Stat3 signaling pathway was abnormal and Stat3 
targeted genes were increased in Gprc5a-/- cells (CHAPTER 3), we investigated 
the status of Stat3 activation in Gprc5a+/+ and Gprc5a-/- cells by analyzing the 
level of tyrosine (residue 705) phosphorylation of Stat3, which is an activated 
form of Stat3. As shown in Fig. 10, we found that Stat3 was more tyrosine 
phosphorylated in Gprc5a-/- cells than in Gprc5a+/+ cells when cultured in K-SFM 
medium supplemented with EGF and BPE for 24 hours, indicating that Stat3 
activation was increased in Gprc5a-/- cells. 
 
4.2 EGF-independent activation of Stat3 in Gprc5a-/- normal airway 
epithelial cells 
 Stat3 can be activated by EGFR signaling (Gao et al., 2007; Politi et al., 
2006). We next investigated whether Stat3 activation in Gprc5a-/- cells was 
mediated by EGF because the serum-free culture medium for the Gprc5a+/+ and 
Gprc5a-/- cells contains EGF as a supplement. We found that EGF signaling 
was activated similarly in these cells as indicated by the transient increase in 
pErk1/2 level when treated with exogenous EGF (Fig. 11A). In contrast, the  
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Figure 10. Stat3 is more activated in Gprc5a-/- normal airway epithelial cells 
than in Gprc5a+/+ cells. Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells 
were cultured in K-SFM supplemented with EGF and BPE for 24 hours, then 
cells were extracted for protein and analyzed for the levels of phosphorylated 
and total Stat3 protein by western blotting. 
 
 
 
 
 
pStat3
(Y705)
Stat3
Gprc5a : +/+ -/-
Medium with EGF
 - 42 -
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. EGF does not stimulate Stat3 activation in Gprc5a-/- and Gprc5a+/+ 
normal airway epithelial cells. A, Gprc5a+/+ and Gprc5a-/- normal airway 
epithelial cells were starved in K-SFM overnight and then treated with EGF at 
10 ng/ml for up to 3 hours. Cells were extracted for protein and analyzed for the 
levels of phosphorylated and total Stat3, phosphorylated and total Erk1/2, and 
actin by western blotting.  B, Gprc5a+/+ and Gprc5a-/- normal airway epithelial 
cells were starved in K-SFM overnight and then treated with EGF at 10 ng/ml 
for up to 12 hours. Cells were extracted for protein and analyzed for the levels 
of phosphorylated and total Stat3 by western blotting.   
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level of tyrosine phosphorylated Stat3, which was higher in Gprc5a-/- cells than 
in Gprc5a+/+ cells before EGF treatment, decreased 30 min after EGF addition 
and began to increase slightly after 3 hours (Fig. 11A)  suggesting that EGFR 
activation does not directly mediate Stat3 phosphorylation in either of these 
cells. The surprising decrease in tyrosine phosphorylation of Stat3 early after 
EGF treatment of the Gprc5a-/- cells was reversed after longer incubation (> 3 
hours) and remained high up to 12 hours (Fig. 11B). A similar response pattern 
but with a substantially lower level of tyrosine phosphorylation of Stat3 was also 
observed in Gprc5a+/+ cells when treated with EGF. Because in this experiment, 
we replaced the “old ”  EGF-free cell growth medium with fresh EGF-
supplemented medium, we surmised that the transient decrease in the level of 
tyrosine phosphorylated Stat3 is due to removal of autocrine factor(s) from the 
conditioned medium (“old”). Indeed, we found that Stat3 was activated in 
Gprc5a-/- cells cultured in medium without EGF for 24 hours but the level of 
tyrosine phosphorylated Stat3 decreased sharply in parallel cultures one hour 
after replacing culture medium conditioned for the preceding 23 hours with fresh 
medium containing no EGF (Fig. 12A and 12B). These results indicate that the 
higher Stat3 activation in Gprc5a-/- cells is EGF-independent but autocrine-
dependent. 
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Figure 12. Stat3 is activated in Gprc5a-/- normal airway epithelial cells 
independent of EGF. A, Gprc5a+/+ and Gprc5a-/- cells were cultured in K-SFM 
and harvested after 24 hours. In parallel cultures, the cells were cultured for 23 
hours and then their “old” medium was replaced with fresh medium and the 
cells were incubated in this medium for one hour.  The cells were harvested and 
analyzed for phosphorylated and total Stat3 by western blotting. B, the X-ray 
films (panel A) were scanned and the bands were quantified using Quantity 
One software. The ratios of phosphorylated Stat3 to total Stat3 were calculated 
and shown in bar graph. 
 
 
 
 
1 24 1
pStat3
(Y705)
Stat3
24
1 24 1 24
+/+ -/-
pS
ta
t3
(Y
70
5)
 / 
St
at
3
Gprc5a :
0
0.2
0.4
0.6
0.8
+/+ -/-Gprc5a :
Growth in serum-free
medium without EGF
Hour
A B
Hour
 - 45 -
4.3 Differential response to the conditioned media mediated the hyper 
activation of Stat3 in Gprc5a-/- normal airway epithelial cells 
 We have shown that the Stat3 activation in Gprc5a-/- cells is dependent 
on autocrine signaling but not on EGF signaling. We then investigated why 
Stat3 is more activated in Gprc5a-/- cells compared to Gprc5a+/+ cells. There are 
two possibilities for the differential activation of Stat3 between these cells. One 
is that the Gprc5a-/- cells secrete a Stat3 activator(s) into their conditioned 
medium whereas the Gprc5a+/+ cells did not. The other is that both cells secrete 
a Stat3 activator(s) into their conditioned medium but the responses to the Stat3 
activator(s) of Gprc5a+/+ and Gprc5a-/- cells were different. We treated both cell 
lines with conditioned media from Gprc5a+/+ and Gprc5a-/- cells and observed 
that both conditioned media activated Stat3 to a very high level in Gprc5a-/- cells 
but only to an extremely low level  in Gprc5a+/+ cells (Fig. 13A and 13B). These 
data strongly suggest that the difference of Stat3 activation between the 
Gprc5a+/+ and Gprc5a-/- cells is due to different response to the Stat3 activator(s) 
in these conditioned media. 
 
4.4 JAK is required for the activation of Stat3 in Gprc5a-/- normal airway 
epithelial cells 
 We next examined whether Stat3 is activated by JAK-mediated cytokine 
signaling. First, we treated Gprc5a-/- cells with AG490, an inhibitor of JAK 
kinase, which is the important mediator of Stat3 activation induced by cytokines.  
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Figure 13. Stat3 is highly activated in Gprc5a-/- normal airway epithelial cells 
induced by conditioned media from Gprc5a+/+ or Gprc5a-/- cells. A, Gprc5a+/+ 
and Gprc5a-/- normal airway epithelial cells were incubated in medium 
conditioned for 24 hours by other cultures of either Gprc5a+/+ or Gprc5a-/- cells 
as indicated. The cells were harvested after one hour and analyzed for 
phosphorylated and total Stat3 by western blotting. B, the X-ray films (panel A) 
were scanned and the bands were quantified using Quantity One software. The 
ratios of phosphorylated Stat3 to total Stat3 were calculated and shown in bar 
graph. 
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Figure 14. Stat3 activation in Gprc5a-/- normal airway epithelial cells is inhibited 
by JAK inhibitor AG490. Gprc5a-/- normal airway epithelial cells were treated 
with AG490 at 30 μM or DMSO (0.1% V:V) in K-SFM without supplements for 
24 hours. The cells were harvested and analyzed for phosphorylated and total 
Stat3 by western blotting.  
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We found that treatment of Gprc5a-/- cells with AG490 for 24 hours completely 
blocked the activation of Stat3 in these cells (Fig. 14).  This result indicates that 
Stat3 activation in Gprc5a-/- cells is dependent on JAK and suggests that Stat3 
may be activated by autocrine cytokines. 
 
4.5 Inhibition of Stat3 activation in Gprc5a-/- normal airway epithelial cells 
by neutralizing antibody against Lif 
 Cytokines of the IL-6 family members like IL-6, LIF and OSM are well 
known activators of STAT3 (Yu et al., 2009). To identify the cytokine(s) which 
activated Stat3 in the Gprc5a-/- cells, we treated the cells with neutralizing 
antibodies against Il-6, Lif and Osm for 24 hours. As can be seen in Fig. 15A 
and 15B, neutralizing antibody against mouse Lif decreased the tyrosine 
phosphorylation of Stat3 in Gprc5a-/- cells compared to the normal goat IgG 
treatment whereas the neutralizing antibodies against Il-6 and Osm did not. 
These data indicate that Lif may be the main autocrine activator of Stat3 in the 
Gprc5a-/- cells. 
 
4.6 Neutralizing antibody against Lif inhibited the Stat3 activation in 
Gprc5a-/- cells induced by both conditioned media from Gprc5a+/+ and 
Gprc5a-/- cells 
 We have shown that conditioned media from Gprc5a+/+ and Gprc5a-/- 
cells activated Stat3 to a similar level (Fig. 13A and 13B) and Lif may be the 
autocrine Stat3 activator in the Gprc5a-/- cells (Fig. 15). We next examined  
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Figure 15. Stat3 activation in Gprc5a-/- normal airway epithelial cells is 
decreased by neutralizing antibody against mouse Lif. A, Gprc5a-/- normal 
airway epithelial cells were cultured in K-SFM with neutralizing antibodies 
against mouse Il-6, Lif, and Osm or with normal goat IgG (all at 30 μg/ml) for 24 
hours. The cells were harvested and analyzed for phosphorylated and total 
Stat3 by western blotting. B, the X-ray films (panel A) were scanned and the 
bands were quantified using Quantity One software. The ratios of 
phosphorylated Stat3 to total Stat3 were calculated and shown in bar graph. 
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Figure 16. Neutralizing antibody against mouse Lif inhibited conditioned 
medium-induced Stat3 activation in Gprc5a-/- normal airway epithelial cells. A, 
24-hour conditioned media from Gprc5a+/+ and Gprc5a-/- cell cultures were 
treated for 1 hour with Lif neutralizing antibody or with normal goat IgG (both at 
30 μg/ml). These media were used to treat Gprc5a-/- cells that had been starved 
for one hour by incubation in fresh K-SFM. After 1 hour of incubation with the 
treated media and the cells were analyzed for phosphorylated and total Stat3 by 
western blotting. B, the X-ray films (panel A) were scanned and the bands were 
quantified using Quantity One software. The ratios of phosphorylated Stat3 to 
total Stat3 were calculated and shown in bar graph. 
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whether Lif was also the autocrine Stat3 activator in the conditioned medium 
from Gprc5a+/+ cells. As shown in Fig. 16A and 16B, we observed a similar 
result as in Fig. 13 in that both conditioned media from Gprc5a+/+ and Gprc5a-/- 
cells activated Stat3 in the Gprc5a-/- cells but did not in the Gprc5a+/+ cells 
indicating that these results were reproducible. Pre-incubating the conditioned 
medium from Gprc5a-/- cells with a neutralizing antibody against Lif for one hour 
inhibited the conditioned media-induced Stat3 activation in Gprc5a-/- cells while 
pre-incubating with the goat normal IgG did not (Fig. 16A and 16B), supporting 
our hypothesis that Lif is the autocrine Stat3 activator in the Gprc5a-/- cells. 
Notably, we found that pre-incubating the conditioned medium from Gprc5a+/+ 
cells with neutralizing antibody against Lif for one hour also inhibited this 
conditioned medium induced Stat3 activation in Gprc5a-/- cells while pre-
incubating with the goat normal IgG did not (Fig. 16A and 16B), indicating that 
Lif is also the autocrine Stat3 activator in the conditioned medium from 
Gprc5a+/+ cells. These data also suggest that the Gprc5a+/+ and Gprc5a-/- cells 
have different response to the autocrine Lif in the conditioned media leading to 
the difference in Stat3 activation between these cells. 
 
4.7 Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells secrete Lif 
 We have shown that Lif-neutralizing antibodies suppressed the autocrine 
Stat3 activation in both Gprc5a+/+ and Gprc5a-/- cells. To obtain more direct 
evidence that both cells secreted Lif into their conditioned media, we collected  
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Figure 17. Gprc5a+/+ and Gprc5a-/- normal airway epithelial cells secrete Lif.  
Gprc5a+/+ and Gprc5a-/- cells were cultured in fresh K-SFM at 2 x 105 per 35-
mm diameter well and their conditioned media were collected after 0, 1, 3, 6, 12, 
and 24 hours and analyzed by ELISA for secreted Lif.  
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conditioned media conditioned for different time from both cells and analyzed 
the Lif levels using ELISA. As seen in Fig 17, Lif existed in both the conditioned 
media from Gprc5a+/+ and Gprc5a-/- cells indicating that Lif could be the Stat3 
activator in these conditioned media. The level of Lif in the conditioned media 
increased following the increasing conditioned time indicating the Lif was 
produced and secreted by these cells than acted as an autocrine factor and 
was not derived from the culture medium (Fig. 17). We also observed that 
Gprc5a-/- cells secreted more Lif into their conditioned medium than Gprc5a+/+ 
cells (Fig. 17). 
 
4.8 Differential response to Lif underlies the persistent Stat3 activation in 
Gprc5a-/- compared to Gprc5a+/+ normal airway epithelial cells  
 We have shown that the Gprc5a+/+ and Gprc5a-/- cells responded 
differently to autocrine Lif. To further confirm our finding, we treated both cells 
with exogenous Lif for one hour and found that Lif activated Stat3 in the Gprc5a-
/- cells whereas no Stat3 activation was observed in the Gprc5a+/+ cells (Fig. 18). 
The Stat3 activation increased when increasing the dose of Lif from 250 to 
10000 unit/ml suggesting Stat3 activation induced by the exogenous Lif was 
dose-dependent between these concentrations (Fig. 18). We then treated both 
cells with exogenous Lif at 1000 units/ml, which is the concentration for 
culturing mouse stem cells in vitro, for different times to monitor the time course 
response of these cells to Lif. We found that Stat3 activation was transient in 
the Gprc5a+/+ cells, peaking around 30 min and declining rapidly by 60 min  
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Figure 18. Dose response of Gprc5a+/+ and Gprc5a-/- normal airway epithelial 
cells to exogenous Lif.  Gprc5a+/+ and Gprc5a-/- cells were starved in fresh K-
SFM for one hour, then treated with different doses of exogenous Lif for one 
additional hour. The cells were then analyzed for phosphorylated and total Stat3 
by western blotting. 
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Figure 19. Gprc5a-/- normal airway epithelial cells have prolonged response to 
exogenous Lif compared with Gprc5a+/+ cells.  A, Gprc5a+/+ and Gprc5a-/- cells 
were starved in fresh K-SFM for one hour, then treated with exogenous Lif (at 
1000 unit/ml) for the indicated times. The cells were analyzed for 
phosphorylated and total Stat3 by western blotting. B, the X-ray films (panel A) 
were scanned and the bands were quantified using Quantity One software. The 
ratios of phosphorylated Stat3 to total Stat3 were calculated and shown. 
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(Fig. 19A and 19B). In contrast, Stat3 activation in Gprc5a-/- cells was 
persistent; after peaking at 30 min it remained activated for at least 90 min (Fig. 
19A and 19B). These results suggest that Gprc5a loss leads to a prolonged 
response to Lif as indicated by persistent Stat3 activation that was also reported 
to occur in various tumor cells (Lee et al., 2009). 
 
4.9 Autocrine Lif mediates Stat3 activation in MDA959 lung tumor cells 
 We have shown that Stat3 was activated in Gprc5a-/- normal airway 
epithelial cells induced by autocrine Lif. Next we investigated whether Stat3 was 
also activated in tumors from Gprc5a-/- mice. We established a mouse lung 
tumor cell line (MDA959) from a spontaneously-developed mouse lung 
adenocarcinoma from a Gprc5a-/- mouse. We found that MDA959 tumor cells 
had a constitutively active Stat3, which was completely inhibited by AG490 (Fig. 
20A), implicating the Jak/Stat3 signaling pathway in this activation. To examine 
whether the Stat3 activation in MDA959 tumor cells was also mediated by 
autocrine Lif, we pre-incubating the conditioned medium from MDA959 tumor 
cells with neutralizing antibody against Lif and found that the antibody 
decreased the tyrosine phosphorylation of Stat3 induced by conditioned 
medium from MDA959 tumor cells (Fig. 20B). To validate that MDA959 tumor 
cells also secreted Lif, we analyzed the level of Lif in the conditioned medium 
from MDA959 tumor cells using ELISA and found that the MDA959 tumor cells 
also released Lif into their conditioned medium as shown in Fig. 21.  
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Figure 20. Lif mediates Stat3 activation in MDA959 mouse lung tumor cells.  A, 
MDA959 cells were treated with 30 μM AG490 or DMSO for 24 hours. The cells 
were analyzed for phosphorylated and total Stat3 by western blotting. B, 24 
hours conditioned medium from MDA959 cell cultures was treated for 1 hour 
with Lif neutralizing antibody or with normal goat IgG (both at 30 μg/ml). These 
media were used to treat MDA959 cells that had been starved for one hour by 
incubation in DMEM/F12 medium without serum. After 1 hour of incubation with 
the treated media the cells were analyzed for phosphorylated and total Stat3 by 
western blotting. 
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Figure 21. MDA959 mouse lung tumor cells secreted Lif.  MDA959 cells were 
cultured in DMEM/F12 for 24 hours and then the medium was collected and 
analyzed for secreted Lif by ELISA. DMEM/F12 medium without conditioning by 
cells was used as a control. * means P < 0.05. 
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4.10 Stat3 activation in Gprc5a-/- normal airway epithelial cells was 
inhibited by dominant negative Stat3  
 We have shown that Stat3 was activated by autocrine Lif in Gprc5a-/- 
cells, and then we investigated whether dominant negative Stat3 can block the 
activation of Stat3 in the Gprc5a-/- cells. Gprc5a-/- cells expressing the dominant 
negative Stat3 (Y705F) were established by transfecting the cells with the Stat3 
(Y705F) expression vector and selecting with hygromycin. Meanwhile, a control 
cell line was also established by transfecting the cells with the empty vector. 
The expression of the dominant negative Stat3 (Y705F) was confirmed by 
western blotting (Fig. 22A). We observed that the mutated Stat3 (Y705F) 
inhibited the activation of the endogenous Stat3 in Gprc5a-/- cells as indicated 
by the decreased level of tyrosine phosphorylated Stat3 compared to the vector 
control (Fig. 22A). The increased total Stat3 protein in the Stat3 (Y705F) 
transfected cells was caused by the fact that the antibody for total Stat3 also 
recognized the dominant negative form of Stat3 (Y705F). Moreover, we found 
that the expression of Stat3 (Y705F) suppressed the expression of the Stat3-
regulated anti-apoptotic proteins (Fig. 22A).  Since Stat3 regulated these anti-
apoptotic genes at transcriptional level, we analyzed the mRNA levels of these 
genes and found the mRNA of these genes also decreased significantly in 
Gprc5a-/- cells expressing the dominant negative Stat3 (Y705F) compared to 
the vector control (Fig. 22B). These data indicate that the upregulation of these 
anti-apoptotic genes in Gprc5a-/- cell compared to the Gprc5a+/+ cells resulted 
from the increased activation of Stat3 in Gprc5a-/- cells. 
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Figure 22. Dominant negative Stat3 inhibits Stat3 activation in Gprc5a-/- normal 
airway epithelial cells.  A, Gprc5a-/- cells transfected with vector or Stat3(Y705F) 
were starved for 48 hours then extracted and analyzed by western blotting for 
the indicated proteins. B, Gprc5a-/- cells transfected with vector or Stat3(Y705F) 
were starved for 48 hours then extracted for mRNA analysis by QPCR for Stat3 
regulated genes. The experiments were done by triplicates and * means P < 
0.05. 
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4.11 Dominant negative Stat3 increases starvation induced apoptosis and 
decreases colony formation in Gprc5a-/- normal airway epithelial cells 
 Next, we investigated whether inhibition of Stat3 activation by dominant 
negative Stat3 (Y705F) would reverse the transformed phenotypes in Gprc5a-/- 
cells. As shown in Fig. 23A and 23B, Gprc5a-/- cells expressing the dominant 
negative Stat3 (Y705F) were significantly more sensitive to starvation induced 
apoptosis compared to cells transfected with the control vector. The starvation 
induced apoptosis rate increased from 9.3% to 22.4% in Gprc5a-/- cells after 
transfected with the dominant negative Stat3 (Y705F). These data indicate that 
persistent Stat3 activation is required for the resistance to starvation induced 
apoptosis in Gprc5a-/- cells. Moreover, we found that Gprc5a-/- cells expressing 
the dominant negative Stat3 (Y705F) formed less colonies in Matrigel than cells 
expressed the control vector (Fig. 24A). The decrease was statistically 
significant and more than 3 folds (Fig. 24B). These data indicate that persistent 
Stat3 activation is also required for the increased colony formation in Gprc5a-/- 
cells. 
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Figure 23. Dominant negative Stat3 increases starvation-induced apoptosis in 
Gprc5a-/- normal airway epithelial cells.  A, Gprc5a-/- cells transfected with vector 
or Stat3(Y705F) were cultured in K-SFM without supplements for 48 hours, then 
cells were double staining with PI and AnnV-FITC and then analyzed  for 
apoptosis by flow cytometry. Results of one of the triplicates is presented. B, 
the mean ± SD of three independent experiments in panel A was shown in bar 
graph. P value were calculated using Student T-test and * means P < 0.05.   
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Figure 24. Dominant negative Stat3 inhibits colony formation of Gprc5a-/- normal 
airway epithelial cells.  A, Gprc5a-/- cells transfected with vector or Stat3(Y705F) 
were suspended in Matrigel and cultured for two weeks to assay their colony 
formation ability. Photomicrographs of cultures at high magnification of one 
experiment were showed. B, colonies in three wells (each cell line) in panel A 
were counted and the data are presented in bar graph as mean ± SD 
colonies/well. P value were calculated using Student T-test and * means P < 
0.05.   
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4.12 Dominant negative Stat3 blocks Stat3 activation; increases starvation 
induced apoptosis and decreases colony formation in MDA959 lung tumor 
cells 
 We have shown that autocrine Lif mediated persistent Stat3 activation 
also existed in MDA959 tumor cells, and then we investigated whether 
dominant negative Stat3 can block the activation of Stat3 in the MDA959 tumor 
cells. MDA959 tumor cells expressing the dominant negative Stat3 (Y705F) 
were established by transfecting the cells with the Stat3 (Y705F) expression 
vector and selecting with hygromycin. Meanwhile, a control cell line was also 
established by transfecting the cells with the empty vector. The expression of 
the dominant negative Stat3 (Y705F) was confirmed by western blotting (Fig. 
25A). We observed that mutant Stat3 (Y705F) inhibited the activation of the 
endogenous wildtype Stat3 in MDA959 cells as indicated by the decreased 
level of tyrosine phosphorylated Stat3 compared to the vector control (Fig. 25). 
The increased total Stat3 protein in the Stat3 (Y705F) transfected cells was 
caused by the fact that the antibody for total Stat3 also recognized the dominant 
negative form of Stat3 (Y705F).  
 Next, we investigated whether inhibition of Stat3 activation by dominant 
negative Stat3 (Y705F) would reverse the transformed phenotypes in MDA959 
tumor cells. As shown in Fig. 26A and 26B, MDA959 tumor cells expressing the 
dominant negative Stat3 (Y705F) were significantly more sensitive to starvation 
induced apoptosis compared to cells transfected with the empty vector. The 
starvation induced apoptosis rate increased from 11.0% to 24.2% in MDA959  
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Figure 25. Dominant negative Stat3 inhibits Stat3 activation in MDA959 mouse 
lung tumor cells. MDA959 tumor cells transfected with vector or Stat3(Y705F) 
were starved for 48 hours then extracted and analyzed by western blotting for 
the indicated proteins. Flag antibody was used to detect the dominant negative 
Stat3(Y705F). 
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Figure 26. Dominant negative Stat3 increases starvation-induced apoptosis in 
MDA959 mouse lung tumor cells.  A, MDA959 cells transfected with vector or 
Stat3(Y705F) were cultured in MDEM/F12 medium without FBS for 48 hours, 
then cells were double stained with PI and AnnV-FITC and analyzed for 
apoptosis by flow cytometry. Results of one of the triplicates is presented. B, 
the mean ± SD of three independent experiments in panel A was shown in bar 
graph. P value were calculated using Student T-test and * means P < 0.05.   
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Figure 27. Dominant negative Stat3 inhibited colony formation of MDA959 
mouse lung tumor cells.  A, MDA959 tumor cells transfected with vector or 
Stat3(Y705F) were suspended in Matrigel and cultured for two weeks to assay 
for colony formation ability. Photomicrographs of cultures at high magnification 
of one experiment were showed. B, colonies in three wells (each cell line) in 
panel A were counted and the data are presented in bar graph as mean ± SD 
colonies/well. P value were calculated using Student T-test and * means P < 
0.05.   
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tumor cells after transfected with the dominant negative Stat3 (Y705F). These 
data indicate that persistent Stat3 activation is required for the resistance to 
starvation-induced apoptosis in MDA959 tumor cells. Moreover, we found that 
MDA959 tumors cells expressed the dominant negative Stat3 (Y705F) formed 
less colonies in Matrigel than cells expressed the control vector (Fig. 27A). The 
decrease was statistically significant and more than 3 folds (Fig. 27B). These 
data indicate that persistent Stat3 activation is also required for the increased 
colony formation in MDA959 tumor cells. 
 
4.13 AG490 increases starvation induced apoptosis and decreased colony 
formation in Gprc5a-/- normal airway epithelial cells 
 We have shown that AG490, an inhibitor of JAK, completely inhibited 
Stat3 activation in Gprc5a-/- cells (Fig. 14). Thus, we also examined whether this 
small molecular inhibitor can reverse the transformed phenotypes in Gprc5a-/- 
cells. As seen in Fig. 28A and 28B, AG490 treatment dramatically increased the 
starvation induced apoptosis in Gprc5a-/- cells. The starvation induced 
apoptosis rate increased from 10.6% to 38.1% in Gprc5a-/- cells after treatment 
with AG490. Meanwhile, we also found AG490 treatment significantly inhibited 
the colony formation ability of Gprc5a-/- cells in Matrigel (Fig. 29A and 29B). 
These data indicate that using small molecular inhibitor of Stat3 signaling also 
can reverse the transformed phenotypes in Gprc5a-/- cells. 
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Figure 28. Inhibition of Stat3 activation using AG490 increases starvation 
induced apoptosis in Gprc5a-/- normal airway epithelial cells. A, Gprc5a-/- cells 
were treated with AG490 (30 μM) or DMSO in K-SFM for 48 hours, then cells 
were double stained with PI and AnnV-FITC and then analyzed  for apoptosis 
by flow cytometry. Results of one of the triplicates is presented. B, the mean ± 
SD of three independent experiments in panel A was shown in bar graph. P 
value were calculated using Student T-test and * means P < 0.05.   
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Figure 29. Inhibition of Stat3 activation using AG490 decreases colony 
formation of Gprc5a-/- normal airway epithelial cells. A, Gprc5a-/- cells were 
suspended in Matrigel with AG490 (30μM) or DMSO and analyzed for colony 
formation over two weeks. Photomicrographs of cultures at high magnification 
of one experiment were showed. B, colonies in three wells (each cell line) in 
panel A were counted and the data are presented in bar graph as mean ± SD 
colonies/well. P value were calculated using Student T-test and * means P < 
0.05.  
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4.14 AG490 increases starvation induced apoptosis and decreases colony 
formation in MDA959 lung tumor cells 
 We have shown that AG490, an inhibitor of JAK, completely inhibited 
Stat3 activation in MDA959 tumor cells (Fig. 20A). Thus we examined whether 
inhibition of Stat3 by this small molecular inhibitor can reverse the transformed 
phenotype in MDA959 tumor cells. As seen in Figs. 30A and 30B, AG490 
treatment significantly increased the starvation induced apoptosis in MDA959 
tumor cells. The starvation induced apoptosis rate increased from 14.3% to 
43.9% in MDA959 tumor cells after treated with AG490. Meanwhile, we also 
found AG490 treatment dramatically inhibited the colony formation of MDA959 
tumor cells in Matrigel (Fig. 31A and 31B). These data indicate that using small 
molecular inhibitor of Stat3 signaling also can reverse the transformed 
phenotypes in MDA959 tumor cells. 
 
4.15 Discussion 
 The relative resistance of Gprc5a-/- normal airway epithelial cells to 
starvation-induced apoptosis compared to Gprc5a+/+ normal airway epithelial 
cells suggests increased self-sufficiency in growth signals, enhanced ability to 
evade apoptosis or both (Hanahan and Weinberg, 2000). The increased 
expression of anti-apoptotic Stat3 target genes including Bcl-XL, Cryab, Hspa1a, 
and Mcl1 in the Gprc5a-/- cells is a likely explanation for their relative resistance 
to apoptosis. Because Stat3 activation has been reported to play important  
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Figure 30. Inhibition of Stat3 activation using AG490 increases starvation 
induced apoptosis in MDA959 mouse lung tumor cells. A, MDA959 cells were 
treated with AG490 (30 μM) or DMSO in DMEM/F12 medium without FBS for 
48 hours, then cells were double staining with PI and AnnV-FITC and then 
analyzed  for apoptosis by flow cytometry. Results of one of the triplicates is 
presented. B, the mean ± SD of three independent experiments in panel A was 
shown in bar graph. P value were calculated using Student T-test and * means 
P < 0.05.   
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Figure 31. Inhibition of Stat3 activation using AG490 decreases colony 
formation of MDA959 mouse lung tumor cells. A, MDA959 cells were 
suspended in Matrigel with AG490 (30μM) or DMSO and analyzed for colony 
formation over two weeks. Photomicrographs of cultures at high magnification 
of one experiment are showed. B, colonies in three wells (each cell line) in 
panel A were counted and the data are presented in bar graph as mean ± SD 
colonies/well. P value were calculated using Student T-test and * means P < 
0.05.  
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roles in both mouse and human lung cancer development (Gao et al., 2007; Li 
et al., 2007) and these increased anti-apoptotic genes in Gprc5a-/- cells were 
Stat3 targeted genes, we examined the status of Stat3 activation in our cells 
and found that Stat3 signaling pathway was activated in Gprc5a-/- cells to a 
much higher level than in Gprc5a+/+ cells. Previous reports have shown that the 
EGFR signaling activated Stat3 and mediated growth in tumor cells (Akca et al., 
2006; Colomiere et al., 2009; Gao et al., 2007; Vigneron et al., 2008). However, 
the Stat3 activation in Gprc5a-/- normal airway epithelial cells was independent 
of exogenous EGF and EGFR signaling but was dependent on autocrine Stat3 
activator(s) released by both Gprc5a+/+ and Gprc5a-/- cells.  
 Further studies using the Jak/Stat3 inhibitor AG490 demonstrated that 
Jak activity is required for Stat3 activation in Gprc5a-/- cells, and identified Lif, a 
member of the Il-6 family cytokines, as the autocrine mediator of Stat3 
activation in the Gprc5a-/- cells. Previous reports have shown that human 
carcinoma cell lines including lung cancer produce Lif (Kamohara et al., 1994) 
and that Lif functions as an autocrine or paracrine growth factor in breast, 
pancreas and glioblastoma tumor cells (Kamohara et al., 2007; Kellokumpu-
Lehtinen et al., 1996; Penuelas et al., 2009; Quaglino et al., 2007). Lif also 
plays important roles in tumor metastasis (Maruta et al., 2009; Wysoczynski et 
al., 2007). Our studies have shown that while both Gprc5a+/+ and Gprc5a-/- cells 
produce and release Lif, their response to Lif was different insofar as Lif 
induced a persistent Stat3 activation in the Gprc5a-/- cells but only a transient 
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activation of Stat3 in the Gprc5a+/+ cells. The data is consistent with the 
previous report that transformed bronchia epithelial cells have increased stat3 
activation induced by LIF (Loewen et al., 2005). This difference in Stat3 
activation may explain the higher levels of the anti-apoptotic genes and proteins 
and the partial resistance of the cells to starvation. Moreover, we also found 
that Stat3 was constitutively activated by autocrine Lif in MDA959 lung tumor 
cells suggesting that Lif mediated Stat3 activation happened in both 
premalignant and malignant cells. 
 The importance of Stat3 activation for the expression of the transformed 
phenotype in Gprc5a-/- normal airway epithelial cells and in MDA959 tumor cells 
was demonstrated by the finding that blocking Stat3 activation by dominant 
negative Stat3(Y705F) or by AG490 increased the sensitivity of both cell lines to 
starvation-induced apoptosis and decreased their colony forming potential. 
Therefore, we propose that persistent Stat3 activation induced by autocrine Lif 
in Gprc5a-/- cells and MDA959 tumor cells may play important roles for the 
development of lung cancer in the Gprc5a-/- mice. This possibility is also 
supported by the report that transgenic mice overexpressing constitutively 
activated Stat3 in alveolar type II epithelial cells develop spontaneous lung 
adenocarcinomas (Li et al., 2007), which suggests that Stat3 activation alone 
can lead to lung carcinogenesis. The relevance of the findings with mouse cells 
to human lung cancer is indicated by the findings that STAT3 is persistently 
activated by chronic stimulation of JAK by cytokines in a variety of human 
tumors including lung tumors (Bromberg et al., 1999; Hedvat et al., 2009). 
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Further, STAT3 target genes have been proposed as biomarkers for human 
chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma 
diagnosis and prognosis (Qu et al., 2009). 
 We have shown that autocrine Lif is the Stat3 activator in Gprc5a-/- cells 
and MDA959 tumor cells. These data were mostly based on studies of cells 
cultured in vitro. To further investigate the important roles of autocrine Lif in lung 
carcinogenesis of Gprc5a-/- mice in vivo, it would be worthwhile to generate 
Gprc5a-/-Lif-/- double knockout mice by crossing the Gprc5a-/- mice with Lif-/- 
mice (Escary et al., 1993; Stewart et al., 1992) and examine whether the 
Gprc5a-/-Lif-/- mice have decreased lung tumors compared with the Gprc5a-/-
Lif+/+ mice. To examine the important roles of persistent Stat3 activation in lung 
carcinogenesis of Gprc5a-/- mice in vivo, we suggest to generate Gprc5a-/-Stat3-
/- double knockout mice by crossing the Gprc5a-/- mice with lung specific Stat3-/- 
mice (Hokuto et al., 2004; Kida et al., 2008) and investigate whether the 
Gprc5a-/-Stat3-/- mice have decreased lung tumors compared with the Gprc5a-/-
Stat3+/+ mice. 
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CHAPTER 5 THE PERSISTENT STAT3 ACTIVATION IN GPRC5A-/- CELLS 
IS THE RESULT OF REDUCED SOCS3 PROTEIN 
 
5.1 Socs3 protein level decreased in Gprc5a-/- normal airway epithelial 
cells compared with Gprc5a+/+ cells 
 Stat3 activation induced by Lif was transient in Gprc5a+/+ cells but 
persistent in Gprc5a-/- cells suggesting that Gprc5a-/- cells have defects in 
controlling the Lif/Stat3 signaling. To explore this further, we examined the level 
of Socs3, a Stat3 induced protein that functions as a negative feedback inhibitor 
of the Stat3 activation induced by various cytokines (Croker et al., 2003; Lang 
et al., 2003; Nicola and Greenhalgh, 2000; Yasukawa et al., 2003). Although we 
did not observe a large difference in the mRNA level of Socs3 between 
Gprc5a+/+ and Gprc5a-/- cells (Fig. 32A), we found that the level of Socs3 protein 
was greatly reduced in Gprc5a-/- cells compared to Gprc5a+/+ cells (Fig. 32B). 
These data suggest that the level of Socs3 is regulated at the post 
transcriptional level. Previous reports have shown that Socs3 protein can be 
degraded through the proteasome pathway (Haan et al., 2003; Sasaki et al., 
2003; Zhang et al., 1999). To determine whether the decreased Socs3 protein 
in Gprc5a-/- cells was caused by increased proteasome mediated degradation, 
we treated cells with the proteasome inhibitor MG132. We found that MG132 
treatment did not increased the protein level of Socs3 in Gprc5a-/- cells and also 
did not change the protein level of Socs3 in Gprc5a+/+ cells (Fig. 33), suggesting 
the Socs3 
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Figure 32. Decreased Socs3 protein level in Gprc5a-/- normal airway epithelial 
cells compared with Gprc5a+/+ cells. A, Gprc5a+/+ and Gprc5a-/- normal airway 
epithelial cells were cultured in K-SFM medium supplemented with EGF and 
BPE for 24 hours, and then cells were harvested and analyzed for Socs3 
mRNA level using QPCR. B, Gprc5a+/+ and Gprc5a-/- normal airway epithelial 
cells were cultured in K-SFM medium supplemented with EGF and BPE for 24 
hours, and then cells were harvested and analyzed for protein level of Socs3 by 
western blotting. 
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Figure 33. Decreased Socs3 protein level in Gprc5a-/- normal airway epithelial 
cells is not caused by increasing proteasome dependent degradation. Gprc5a+/+ 
and Gprc5a-/- normal airway epithelial cells were treated with 10 μM MG132 for 
the indicated times, and then the cells were harvested and analyzed for protein 
level of Socs3 by western blotting. 
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protein is not regulated by proteasome mediated degradation in Gprc5a+/+ and 
Gprc5a-/- cells. 
 
5.2 Restoration of SOCS3 expression in Gprc5a-/- normal airway epithelial 
cells inhibited Stat3 activation 
 To confirm that the persistent Stat3 activation of Stat3 in Gprc5a-/- cells 
was due to a decrease of Socs3, we restored the expression of SOCS3 into 
Gprc5a-/- cells by transfection with a SOCS3-HA expression vector. As can be 
seen in Fig. 34A, the expression of SOCS3-HA was confirmed by 
immunoblotting using HA antibody. We found that the over-expression of 
SOCS3 decreased the persistent activation of Stat3 in Gprc5a-/- cells as 
indicated by the reduced level of tyrosine phosphorylated Stat3 (Fig. 34A). To 
investigate whether over-expression of SOCS3 will change the response to Lif 
stimulation, we treated the cells with exogenous Lif. As shown in Fig. 34B, 
Gprc5a-/- cells expressing SOCS3 exhibited reduced response to exogenous Lif 
stimulation, which is similar to Gprc5a+/+ cells. These data strongly indicate that 
decreased Socs3 protein due to loss of Gprc5a tumor suppressor leads to the 
prolonged response to Lif and persistent activation of Stat3 in Gprc5a-/- cells. 
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Figure 34. SOCS3 inhibits Stat3 activation in Gprc5a-/- normal airway epithelial 
cells. A, Gprc5a-/- cells transfected with vector or SOCS3-HA were starved for 
48 hours then extracted for western blotting analysis of the indicated proteins. B, 
Gprc5a-/- cells transfected with vector or SOCS3-HA were starved in fresh K-
SFM for one hour, then treated with exogenous Lif (1000 unit/ml) for the 
indicated times. The cells were analyzed for phosphorylated and total Stat3 by 
western blotting. 
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5.3 GPRC5A increases SOCS3 protein in co-transfected 293T cells 
 The above data suggested that Gprc5a increased Socs3 protein by  
post-transcriptional regulation. To determine whether human GPRC5A also 
increase SOCS3 protein level, we co-transfected SOCS3 expression vector 
with GPRC5A expression vector in 293T cells. We found that SOCS3 protein 
level increased in cells co-transfected with GPRC5A compared to control vector, 
strongly indicating that GPRC5A may increase SOCS3 protein through post-
transcriptional regulation (Fig. 35). 
 
5.4 GPRC5A stabilizes SOCS3 protein 
 We have shown that SOCS3 protein level was higher in GPRC5A 
expressing cells. We propose that it may be through translational regulation or 
through regulating the stability of the SOCS3 protein. To determine whether 
GPRC5A stabilized SOCS3 protein, we co-expressed SOCS3 with GPRC5A 
and treated the cells with cycloheximide, an inhibitor of protein synthesis. As 
shown in Fig. 36A and 36B, SOCS3 protein degraded more slowly in cells co-
expressing GPRC5A than in cells co-transfected with control vector. The half 
life of SOCS3 increased when co-expressed with GPRC5A relative to co-
transfected with control vector (Fig. 36B). These data indicate that GPRC5A 
increases SOCS3 protein level through regulating the SOCS3protein stability 
and half-life. 
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Figure 35. GPRC5A increased SOCS3 protein level in 293T cells. 293T cells 
were transfected with expression vectors of SOCS3 tagged with Flag, GPRC5A 
tagged with Myc as indicated and cultured for 48 hours. The cells were then 
harvested and analyzed for protein levels of SOCS3, GPRC5A and Actin by 
western blotting. 
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Figure 36. GPRC5A stabilizes SOCS3 protein in 293T cells. A, 293T cells were 
transfected with expression vectors of SOCS3 with Flag tag and vector control, 
or SOCS3 with Flag tag and GPRC5A with Myc tag and cultured for 48 hours. 
Cells were then treated with cycloheximide (CHX) at 20 μM for the indicated 
times then harvested and analyzed for protein levels of SOCS3, GPRC5A and 
Actin by western blotting. B, the X-ray films (panel A) were scanned and the 
bands were quantified using Quantity One software. The intensities 
(percentage) were calculated by comparing to the 0 hour point. The 0 hour point 
is 100%. 
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5.5 SOCS3 co-localizes and interacts with GPRC5A in 293T cells 
 Next, we investigated the locations of SOCS3 and GPRC5A when co-
expressed in 293T cells. We fused SOCS3 with red fluorescence protein DsRed 
and GPRC5A with green fluorescence protein AcGFP1 and co-expressed them 
in 293T cells. As seen in Fig. 37, SOCS3 co-localized with GPRC5A-AcGFP1 
fusion protein but not with AcGFP1 protein, indicating that SOCS3 co-localized 
with GPRC5A protein. The co-localization of SOCS3 and GPRC5A suggested 
that SOCS3 may interact with GPRC5A, which may regulate SOCS3 
stabilization. To determine whether SOCS3 interacts with GPRC5A, we co-
expressed SOCS3 with flag tag and GPRC5A with myc tag in 293T cells and 
performed immunoprecipitation. We found that GPRC5A was associated in the 
SOCS3 protein complex immunoprecipitated using anti-flag antibody, whereas 
the normal IgG did not pull down either SOCS3 or GPRC5A (Fig. 38).  
 
5.6 Discussion 
 The Stat3 activation induced by autocrine Lif was transient in Gprc5a+/+ 
normal airway epithelial but was persistent in Gprc5a-/- cells, suggesting that 
Gprc5a-/- cells may lose some negative feedback inhibitors of the Lif/Stat3 
signaling. Following that, we found that Socs3 protein, a well known inhibitor of  
Stat3 signaling, was decreased in the Gprc5a-/- cells compared to Gprc5a+/+ 
cells which may explain the persistent Stat3 activation induced by autocrine Lif. 
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Figure 37. GPRC5A colocalizes with SOCS3 protein in 293T cells. 293T cells 
were transfected with expression vectors of SOCS3 with DsRed tag and 
GPRC5A with AcGFP tag, or SOCS3 with DsRed tag and AcGFP alone. After 
culturing for 48 hours, cells were fixed, stained for nuclei using DAPI and 
analyzed by using Olympus confocal microscope. 
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Figure 38. GPRC5A interacts with SOCS3 protein in 293T cells. The cells were 
transfected with expression vectors of SOCS3 with Flag tag and GPRC5A with 
Myc tag. After culturing for 48 hours, cells were harvested and cell lysates were 
subjected to immunoprecipitation using Flag antibody or normal IgG. The 
protein complexes were analyzed by western blotting. 
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Previous study showed that SOCS3 was silenced by promoter 
hypermethylation in human head and neck cancer cells and lung cancer (He et 
al., 2003; Weber et al., 2005). However, we found that the reduction of Socs3 
protein in Gprc5a-/- cells was regulated through post-transcriptional level since 
the mRNA level of Socs3 were even somewhat higher in Gprc5a-/- cells 
compared with Gprc5a+/+ cells, which may be explained by the fact that Socs3 
is also a Stat3 targeted gene. Thus, Socs3 level may be down-regulated by 
different pathways including transcriptional or posttranscriptional regulation in 
lung cancer cells.  It has been reported that SOCS3 protein may be degraded 
through the proteasome pathway (Haan et al., 2003; Sasaki et al., 2003). 
However, the proteasome inhibitor MG132 did not alter the Socs3 protein level 
in Gprc5a-/- cells and Gprc5a+/+ cells, consistent with a previous report that wild 
type SOCS3 was degraded through a proteasome-independent pathway  
(Babon et al., 2006). The degradation pathway of wild type SOCS3 and the 
mechanism by which GPRC5A stabilized SOCS3 require further investigation, 
which is out of the scope of this thesis. 
 In summary, we demonstrated a potential mechanism involving Stat3 
activation by which Gprc5a functions as a lung-specific tumor suppressor. In 
Gprc5a+/+ airway epithelial cells (Fig. 39), Socs3 protein is stabilized by Gprc5a 
and negatively regulates the autocrine Lif-induced Stat3 activation leading to a 
transient Stat3 activation in response to the autocrine Lif. The Stat3 regulated 
anti-apoptotic genes are then expressed at a low level and the Gprc5a+/+ airway 
epithelial cells are  
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Figure 39. Stat3 signaling in Gprc5a+/+ cells. In Gprc5a+/+ cells, Socs3 protein 
was high through Gprc5a-mediated stabilization. The autocrine Lif induced 
Stat3 activation was transient and inhibited by Socs3, leading to low expression 
of anti-apoptotic proteins like Bcl-XL, Cryab, Hspa1a and Mcl1. Thus, the 
Gprc5a+/+ cells were more sensitive to starvation induced apoptosis and grew 
dependent on anchorage. 
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Figure 40. Stat3 signaling in Gprc5a-/- cells. In Gprc5a-/- cells, Socs3 protein 
level is much lower than in Gprc5a+/+ cells due to loss of stability. The autocrine 
Lif induced a persistent activation of Stat3 because of the low level of Socs3, 
the negative feedback inhibitor of the Lif/Stat3 signaling. The persistent Stat3 
activation increased the expression of anti-apoptotic genes including Bcl-XL, 
Cryab, Hspa1a and Mcl1, leading to increased survival, acquisition of 
anchorage independent growth in Gprc5a-/- cells, and lung tumorigenesis in 
Gprc5a-/- mice.  
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more sensitive to starvation induced apoptosis and their growth is anchorage-
dependent. In Gprc5a-/- airway epithelial cells (Fig. 40), Socs3 protein is lower 
than in Gprc5a+/+ cells due to the loss of Gprc5a and the autocrine Lif/Stat3 
pathway is hyper-activated. The Gprc5a-/- airway epithelial cells have a 
prolonged response to autocrine Lif which causes a persistent activation of 
Stat3, leading to the high expressing these Stat3 targeted anti-apoptotic genes 
including Bcl-XL, Cryab, Hspa1a and Mcl1. The Gprc5a-/- airway epithelial cells 
exhibit increased survival and anchorage-independent growth and behavior like 
transformed cells which contributes to the development of spontaneous lung 
tumors in Gprc5a-/- mice. 
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CHAPTER 6 DISCUSSION 
 
6.1 New and unique mouse model of lung cancer 
 Human lung cancer is a dreadful disease causing ~30% of cancer death 
every year. The development of mouse models bearing lung tumors will likely 
bring in additional insights into the pathophysiologic perturbations of lung 
cancer; provide more targets for developing therapy drugs and serve as a good 
in vivo screen system for compounds against lung cancer. Several mouse 
models of lung cancer have been generated using genetic methods by knocking 
in oncogenes like mutant EGFR, mutant Kras and constitive activated Stat3 or 
by knocking out tumor suppressors like p53.  However, p53 tumor suppressor 
knockout mutant animals succumb to other tumors like lymphomas and 
sarcomas in early stage, precluding the development of lung cancer, although 
knockout mutant animals are not embryonic lethal like other tumor suppressor 
Rb-1 and WT-1. Our Gprc5a knockout mutant mouse model is a unique lung 
cancer model since that deletion of Gprc5a, a single tumor suppressor gene, is 
sufficient to mimic the human lung cancer phenotype in the mouse. Moreover, 
Gprc5a functions as a lung-specific tumor suppressor because it is primary 
expressed in mouse lung tissue and no other organs developed tumors in 
Gprc5a-/- mice.  
 Human lung cancer patients are usually diagnosed at advanced stage 
with metastasis diseases, which are important reason for lung cancer death. 
Gprc5a is not a metastasis inhibitor since Gprc5a-/- mice do not show 
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metastasis at later stage so that we can not work on lung cancer metastasis just 
on the Gprc5a-/- mice. However, we can investigate the mechanisms of other 
factors which have effect on lung cancer metastasis using the combination of 
Gprc5a-/- mutant mice with other transgenic mice. It has been reported that 
combination of mutant p53 with Kras mutant or combination of knockout LKB 
with Kras mutant increased lung cancer metastasis. It is unknown that whether 
mutant p53 or knockout LKB affecting lung cancer metastasis needs the 
specific background on Kras mutant. To address this question, we can generate 
Gprc5a and p53 double mutant mice or Gprc5a and LKB double mutant mice to 
investigate whether mutant p53 or knockout LKB will increase the lung cancer 
metastasis on the Gprc5a-/- background mice. We believe that Gprc5a knock 
out model is better than the Kras model because Gprc5a is primary expressed 
in lung while Kras is expressed in variety tissues so that it will have less none 
specific effects. 
 
6.2 Translational use of Gprc5a-/- lung cancer mouse model 
 Gprc5a-/- mice spontaneously develop lung inflammation and lung 
adenocarcinoma and tobacco-specific carcinogen NNK not only accelerated the 
tumorigenesis but also increased the multiplicity of lung tumors, thus this model 
will be useful for screening and testing drugs for the prevention and therapy of 
lung cancer. Gprc5a function as a protector of tobacco carcinogen induced lung 
cancer and may also serve as a predict marker for lung tumor development of 
smoking people since hundred percentage of Gprc5a-/- mice developed lung 
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tumors when treated with NNK compared with none of Gprc5a+/+ mice 
developed lung cancer. Smoking people with low or none expression of 
GPRC5A will be at higher risk of development of lung cancer relative to 
smoking people with normal expression of GPRC5A.  
 Our finding that Stat3 is persistently activated in Gprc5a-/- normal and 
malignant airway epithelial cells suggests Stat3 inhibitors like Stat3 decoy 
composing of a double-stranded oligonucleotide which corresponded closely to 
the Stat3 response element  may be used to treat lung cancer patient with low 
expression of GPRC5A.  We can also target the upstream of Stat3 activation 
using JAK inhibitors, dominant negative LIF protein and cell permeable SOCS3 
recombinant protein. Gprc5a suppress Stat3 activation by stabilization of Socs3 
protein so that we can identify the domain or small peptides from Gprc5a which 
stabilize Socs3 and will also be good drug for lung cancer treatment. 
 In summary, Gprc5a knockout mice are new and unique mouse model 
for lung cancer providing new targets like LIF and stratagem for lung cancer 
treatment. This model will be a useful tool to study the mechanism of lung 
cancer development and lung cancer metastasis.  
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